Preisverleihung 2017

STIFTUNG
PROFESSOR DR. MAX CLOÈTTA

Heft Nr. 45

Prof. Dr. Denis Jabaudon
«Fate and freedom in the developing neocortex»

Prof. Dr. Markus G. Manz
«Hematopoiesis – A paradigmatic stem cell supported organ system»
INHALT

Vorwort des Präsidenten des Stiftungsrates und der Geschäftsführerin................................................................. 5
Urkunde für Prof. Dr. Denis Jabaudon................................................................. 11
Kurzbiografie von Prof. Dr. Denis Jabaudon......................................................... 13
Festvortrag von Prof. Dr. Denis Jabaudon......................................................... 16
Fate and freedom in the developing neocortex
Urkunde für Prof. Dr. Markus G. Manz................................................................. 43
Kurzbiografie von Prof. Dr. Markus G. Manz......................................................... 45
Festvortrag von Prof. Dr. Markus G. Manz
Hematopoiesis – A paradigmatic stem cell supported organ system. 52
Informationen über die Stiftung Prof. Dr. Max Cloëtta................................. 88
Übersicht über die bisher erschienenen Publikationen der Schriftenreihe Stiftung Professor Dr. Max Cloëtta......................... 90
Ehrentafel der Preisträger.............................................................................101
VORWORT
Prof. Dr. med. Adriano Fontana

Mit Prof. Dr. Denis Jabaudon würdigt die Stiftung Professor Dr. Max Cloetta einen Neurowissenschaftler, welcher im Neurozentrum der Universität Genf die Mechanismen der Entwicklung neuronaler Netzwerke im Hirn untersucht. Insbesondere haben seine bahnbrechenden Studien zur Identifikation von Genen geführt, welche für die funktionelle Verknüpfung von Neuronen in der Hirnrinde und im Thalamus verantwortlich sind.

Der zweite Preisträger ist Prof. Dr. Markus Manz, welchem es in der Klinik für Hämatologie im Universitätsspital Zürich erstmals gelang, von Blutstammzellen ausgehend die Entwicklung von dendritischen Zellen des Immunsystems aufzuzeigen. Darüber hinaus hat er ein weltweit verwendetes Verfahren entwickelt, welches es in Mäusen erlaubt, die Entwicklung und Funktion des Immunsystems des Menschen zu untersuchen.

Wie bereits anlässlich der Verleihung des Cloetta-Preises 2016 hervorgehoben wurde, werden erneut zwei Wissenschaftler ausgezeichnet, deren hervorragende wissenschaftliche Beiträge miteinander durch von ihnen entwickelte technische Durchbrüche gelungen sind. Technik zum einen, Ideenreichtum, Scharfsinn, freudiges Beobachten und Experimentieren zum anderen. Welche Kontraste zur immer mehr um sich greifenden postfaktischen Gesinnung und populistischen Meinungsausserung, mit welcher die Wissensgesellschaft heute konfrontiert ist!

Mit der Verleihung des Cloëtta Preises wird die Leistung von Prof. Dr. Denis Jabaudon und Prof. Dr. Markus Manz gewürdigt. Die Cloëtta Stiftung freut sich, die Preisträger am 3. November 2017 in Zürich zu feiern.
Stiftungsrat


Dr. Peter Weibel, der seit 2012 sein profundes Wissen im Bereich Finanzen und Vermögensverwaltung der Stiftung zur Verfügung gestellt hatte, ist 2017 aus ebendiesem Grund aus dem Stiftungsrat zurückgetreten. Wir danken ihm herzlich für sein grosses Engagement und wünschen ihm ein paar erholsame zusätzliche Momente. Die UZH Foundation, die Dr. Weibel seit ihrer Gründung präsidiert, wird dankbar sein für die zusätzlich zur Verfügung stehende Zeit!

Mit Peter Ochsner konnte die Stiftung ein neues Mitglied gewinnen, das in über 30 Jahren bei PriceWaterhouseCoopers, als Finanzverantwortlicher der Zürcher Festspielstiftung und Verwaltungsrat der Banque Cantonale Vaudoise über ein enorm breites Wissen verfügt. Wir heissen ihn sehr herzlich willkommen und freuen uns auf die kommende Zusammenarbeit!
Cloëtta-Preis

Stiftungsrat und Geschäftsstelle freuen sich, auch dieses Jahr zwei herausragende Forscher mit dem Cloëtta-Preis auszeichnen zu können: Prof. Denis Jabaudon aus Genf und Prof. Markus G. Manz aus Zürich. Letzterer kann die verdiente Auszeichnung «zu Hause» entgegennehmen, denn wir dürfen wieder am UniversitätsSpital Zürich zu Gast sein. An dieser Stelle bedanken wir uns herzlich bei den Verantwortlichen der Universität und ihrem Vertreter in unserem Stiftungsrat, Prof. Dr. Fritjof Helmchen, für ihre Unterstützung.


Herzlichen Glückwunsch allen Preisträgern!

Forschungsstellen

2017 finanzierte die Stiftung Prof. Dr. Max Cloëtta folgende Forscher an Schweizer Universitäten mit fünfjähriger Unterstützungsperiode:


Mit dreieinhalbjähriger Unterstützungsduer:


2017 kommen folgende Medizinerinnen und Mediziner in den Genuss eines Stipendiums (Unterstützung läuft oder wurde 2017 zugesprochen):


Zusammen mit dem Team der Geschäftsstelle freue ich mich, die Stiftung Prof. Dr. Max Cloëtta auch weiterhin in eine aktive Zukunft für die Förderung der medizinischen Forschung in der Schweiz begleiten zu dürfen. Dem Stiftungsrat, der Uniscientia Stiftung, unseren Stipendiatinnen und Stipendiaten und den medizinischen Fakultäten danken wir herzlich für die jederzeit sehr angenehme Zusammenarbeit.
THE CLOËTTA PRIZE 2017
IS AWARDED TO

PROFESSOR

DENIS JABAUDON

BORN IN 1971 IN VEVEY, SWITZERLAND
DIRECTOR OF THE NEUROCENTER OF THE UNIVERSITY
OF GENEVA

FOR HIS GROUND BREAKING FINDINGS ABOUT GENETIC
MECHANISMS GOVERNING ASSEMBLY AND
FUNCTIONAL INTEGRATION OF CORTICAL AND THALAMIC
NEURONS INTO NEURONAL CIRCUITS

Zürich, 5th November 2017

IN THE NAME OF THE FOUNDATION BOARD:

THE PRESIDENT

THE VICE PRESIDENT

MEMBER

A. Forfman

W. Reich

#Reich
BIOGRAPHY

Name: Jabaudon, Denis  
Date of Birth: 30th January 1971  
Place of Birth: Vevey, Switzerland

<table>
<thead>
<tr>
<th>Education</th>
</tr>
</thead>
</table>
| 1989–1995: Medical School | University of Lausanne  
| 1996–1999: MD-PhD Scholar | Brain Research Institute  
| | University of Zürich |

<table>
<thead>
<tr>
<th>Positions</th>
</tr>
</thead>
</table>
| 1999–2004: Neurology Residency | Lausanne and Geneva University Hospitals  
| |  
| 2004–2008: Postdoctoral Fellow | Harvard Medical School  
| | Boston, Massachusetts, USA  
| 2008–2009: Junior Research Fellow (Chef de Clinique Scientifique) | Dept. of Basic Neurosciences  
| | University of Geneva  
| 2008– | Attending Physician | Clinic of Neurology  
| | | Geneva University Hospital  
| 2009–2015: SNSF Assistant Professor | Dept. of Basic Neurosciences  
| | University of Geneva  
| 2015– | Full Professor | Dept. of Basic Neurosciences  
| | University of Geneva |
Denis Jabaudon obtained his MD-PhD degree at the Universities of Lausanne and Zurich in Switzerland, where he studied mechanisms controlling synaptic transmission in the laboratory of Prof. Beat Gähwiler. After a neurology residency at Geneva University Hospital, he completed a post-doctoral fellowship at Harvard University, in the laboratory of Prof. J. Macklis, where he began investigating the genetic mechanisms controlling cortical development.

He is currently a professor at the University of Geneva, Switzerland, since 2009, where he has his independent research group, and also practices as a clinical neurologist at Geneva University Hospital.

His work on the genetics of neuronal circuit assembly during cortical development has earned him several prestigious prizes, including the Freedman Prize for Exceptional Basic Research from the Brain and Behavior Research Foundation (NARSAD), the Pfizer Research Prize, and the Bing Prize from the Swiss Academy of Medical Science. Prof. Jabaudon is currently the Director of the Geneva University Neurocenter; he is a member of the FENS Kavli Network of Excellence and his work is funded by the Swiss National Science Foundation (Project and Consolidator Grants) and the Brain and Behavior Research Foundation.

Work in the Jabaudon laboratory is aimed at understanding how genetic and input-dependent mechanisms interact to control neuronal circuit assembly during development. The approaches his team uses to address these questions include the isolation and genetic characterization of single forebrain neurons subtypes, in vivo genetic manipulations during development and optogenetic interrogation of developing circuits.

The long-term aim of his research is to understand how altered environmental conditions and abnormal gene expression interact to lead to circuit miswiring and behavioral changes in neurodevelopmental and psychiatric disorders.
SELECTED PUBLICATIONS


Summary

The activity of neuronal circuits of the neocortex underlies our ability to perceive the world and interact with our environment. During development, these circuits emerge from dynamic interactions between cell-intrinsic, genetically determined programs, and input/activity-dependent signals, which together shape these circuits into adulthood. Over the past decade or so, technological developments have progressively allowed us to interrogate these nature-nurture interactions with single gene / single input / single cell resolution. In this review, I will discuss some of the genetic and input-dependent mechanisms controlling how individual cortical neurons differentiate into specialized cells to form neuronal circuits and highlight, when appropriate, the contributions we made to this global effort. This monograph is closely adapted from a review I recently published on this topic (Jabaudon 2017).
Introduction

The neuronal circuits of the neocortex underlie our ability to perceive the world and conduct meaningful interactions with our surroundings. Neocortical circuits, through their activity, account for processes such as sensory perception and integration, sensory-motor transformation, motor planning and execution, long-term memory, and attention. These circuits are formed by a diversity of specialized neuronal subtypes, which can be distinguished from each other by anatomical, morphological, physiological, hodological (i.e. relating to connectivity) and genetic features.

Neocortical circuits are both robust and flexible: they reliably carry out complex repetitive tasks, yet are also able to modify the execution of these tasks in response to context and previous experience. To accommodate the seemingly opposing constraints of reliability and plasticity, at least two main driving forces are at play during development: (1) genetically determined processes, which act within single cells and allow the generation and differentiation of a core set of specialized neuronal cell types, and (2) non cell-autonomous, input/activity dependent processes, which act during critical periods of development to refine these neurons into further subtypes, allowing neural circuit diversification and context-dependent expansion of the behavioral repertoire. Balance between these intrinsic developmental programs and external signals is essential for the proper differentiation and assembly of neurons into circuits, yet the dynamic contribution of these two types of processes to cortical development remains unclear.

Over the past decade or so, my laboratory has been interested in teasing out how genetic and circuit-derived factors bidirectionally interact during development to give rise to the neuronal and circuit diversity found in the adult neocortex. In the current monograph, which is closely transcribed and adapted from a review I recently published on this topic (Jabadon 2017), I will first provide an introduction on the cerebral cortex and its cellular diversity, then introduce how different types of input modulate cortical neuron differentiation. Throughout this narrative, as per the tradition of the Max Cloëtta Series, I will highlight some contributions of my laboratory to the understanding of these processes.
The neocortex is organized in layers and areas

The neocortex consists in a thick sheet of neurons which covers the surface of both hemispheres in mammals (Fig. 1). As introduced above, this structure is the place where sensory inputs converge to generate our conscious perception of the outside world, and where voluntary motor actions are planned and initiated. The neocortex is radially organized into layers, which each are enriched in specialized subtypes of neurons, and tangentially organized into areas, which specialize in diverse sensory, motor, and associative functions (Fig. 1). There are six main layers in the neocortex, which have historically been defined by distinct densities of neuronal somas, dendrites and axons. These laminae are not only anatomical landmarks, but actually consist of developmentally and functionally distinct subtypes of glutamatergic neurons (Fig. 1) (Jabaudon 2017; Molyneaux et al. 2007; Harris and Shepherd 2015).

![Figure 1: Areal and laminar organization of the neocortex. (a) Schematic representation of the distinct primary cortical areas in the mouse, and cell-type specific connectivity of cortical projection neurons. A1: primary auditory cortex, CB: Cerebellum, M1: primary motor cortex, SI: primary somatosensory cortex, SC: spinal cord, Th: Thalamus, V1: primary visual cortex. (b) Laminar organization of the neocortex (SI). CUX3 specifically labels intracortical projection neurons while CTIP2 labels corticospinal neurons in layer (L) 5. Taken from Jabaudon, 2017.](image)

The deepest cortical layers contain neurons whose axons target subcortical structures such as the thalamus (corticothalamic neurons, layer (L) 6) and the tectum, hindbrain and spinal cord (“corticospinal” neurons, L5). In contrast, neurons located more superficially in layers 2 and 3
(L2/3), and 4 (L4) have intracortical axonal targets. Neurons in L4 (also called the "granular layer") differ from the neurons present in other layers in that they are locally-projecting glutamatergic interneurons, i.e. they do not send long-range projections. They are the main targets of neurons in exteroceptive sensory thalamic nuclei (i.e. which receive input from the sense organs) (Petreanu et al. 2009; Erzurumlü, Murakami, and Rijli 2010; Vitali and Jabaudon 2014), and, as such, form the principal sensory gateway to the neocortex. L4 neurons are particularly sensitive to impairments of the sensory organs or their input pathways; as will be discussed in detail later, this is particularly striking in the rodent somatosensory cortex. Within this cortical area, whisker-input receiving L4 neurons are clustered into distinct cellular assemblies called “barrels”, which each receive input from a single principal whisker, and are somatotopically distributed such that neighboring barrels receive input from neighboring whiskers (Vitali and Jabaudon 2014; Erzurumlü, Murakami, and Rijli 2010; Pouchelon and Jabaudon 2014). As will be discussed below, in several of my laboratory’s research projects, we are taking advantage of the exquisite sensitivity of L4 neurons to input to study the role of activity-dependent signals in neuronal differentiation and circuit formation (see e.g. Pouchelon et al. 2014; Frangeul et al. 2014; Rossa et al. 2013).

In addition to excitatory glutamatergic neurons, the neocortex contains another population of neurons, which are inhibitory, use another transmitter, GABA, and are born from distinct germinal zones (i.e. proliferative regions where progenitor are located) than excitatory neurons (see below). The diverse populations of GABAergic interneurons play a pivotal role in the gating and spread of cortical signals through processes such as feedforward inhibition, disinhibition and feedback inhibition.

**Cortical areas**

Layers are not homogenous across the rostro-caudal and latero-medial extent of the neocortex. Instead, local cytoarchitecture varies in an often discontinuous way across the tangential surface of the cortex, defining distinct cortical areas. Histological discontinuities are particularly striking in species with large cortices, and form the basis of the classical Brodmann classification of cortical areas (Zilles and Amunts 2010).
Each cortical area is reciprocally connected with a defined subset of inputs from the thalamus, a structure which relays inputs from the different sense organs (e.g. skin mechanoreceptors, retinal photoreceptors, auditory cells in the cochlea, Fig. 2a). Frontally-located cortical areas are connected with frontally-located thalamic nuclei, including those involved in motor planning and execution, while parieto-occipital and temporal cortical areas are interconnected with more posterior thalamic nuclei, and are involved in sensory perception and integration (López-Bendito and Molnár 2003; Clascá, Rubio-Garrido, and Jabaudon 2012). Delineations between individual cortical areas are particularly sharp in areas receiving input from exteroceptive thalamic nuclei, such as the primary somatosensory, visual, and auditory cortices. Because of their characteristic cytoarchitectural features, these primary sensory areas, and particularly the primary somatosensory (S1) and visual (V1) areas have been extensively used as model systems to study the role of input on cortical differentiation. As a consequence, our understanding of thalamocortical organization and information flow is largely based on the connectivity of primary sensory areas, and particularly somatosensory and visual areas, (Frangeul et al. 2016; Kral 2013). However, these areas only represent a small fraction of the total cortical surface, and different connectivities and information flow exist in other cortical areas and thalamic nuclei, as will be detailed in the next section. A significant part of the work in my laboratory has focused on trying to better characterize the relationship between primary exteroceptive regions and secondary, associative regions, and on trying to understand how input acts to shape secondary regions into primary ones, as discussed later in the text (see e.g. Pouchelon et al. 2014; Frangeul et al. 2016).

**Cortical information flow**

Sensation starts with detection of stimulus through activation of peripheral receptors, such as skin mechanoreceptors or retinal photoreceptors. Input from these receptors reaches neurons located in exteroceptive, “first order” thalamic nuclei such as the ventrobasalis nucleus (VB, for tactile stimuli), the dorsolateral geniculate nucleus (LG, for visual stimuli), and the ventral medial geniculate nucleus (vMG, for auditory stimuli). Sensory information then reaches primary sensory areas of the neocortex,
where core stimulus properties are perceived, and is then forwarded to secondary sensory (e.g. S2 and V2) and associational areas where stimulus features are dynamically and multi-modally processed (Fig. 2a).

Within primary sensory areas, first order nuclei project particularly strongly onto L4 neurons, which act as the main entry point of extracortical input (Vitali and Jabaudon 2014). From L4 neurons, information is then split into two parallel streams (Fig. 2b): a “classical”, intracortical stream, and a more recently characterized extracortical stream. In the intracortical stream, signals are sent to distinct subtypes of L2/3 intracortical neurons, which project to specific sets of cortical areas, including S2, V2, and M1; in the other, cortico-thalamo-cortical stream, L4 signals are sent to infragranular L5B neurons, which send top-down projections to non-exteroceptive, “higher-order” thalamic nuclei (posteromedial nucleus (POm), from S1; lateroposterior nucleus or pulvinar (LP) from V1), and dorsal medial geniculate nucleus (dMG), from A1). Higher-order

Figure 2: Cortical information flow. (a) Extroceptive, first-order thalamic nuclei VB, LG (filled in blue) project to primary cortical areas (S1, V1). Higher order thalamic nuclei and secondary cortical areas are outlined in blue. POM: posteromedial thalamic nucleus; LG: dorsolateral geniculate nucleus; LP: lateroposterior nucleus; VB: ventrobasalis nucleus. (b) Two distinct pathways allow inter-area communication: an intracortical pathway (green) and a cortico-thalamo-cortical pathway (purple), originating from L5B cortical neurons and which transits through higher-order thalamic nuclei. Taken from Jabaudon, 2017.
thalamic nuclei in turn project to L4 neurons of secondary sensory (i.e. S2, V2) areas, thus closing a cortico-thalamo-cortical loop (Theyel, Llano, and Sherman 2010; Guillery and Sherman 2002). Higher-order thalamic nuclei do not project exclusively to secondary sensory areas but instead have diffuse connections across many cortical areas (Clasca, Rubio-Garrido, and Jabaudon 2012). As such, they may be involved in the coordination of activity across motor and somatosensory cortices during active sensing, as occurs when mice sweep their whiskers back and forth to generate a tactile representation of their environment.

Interestingly, these two main inter-areal communication pathways have distinct evolutionary histories, since supragranular intracortical projection neurons are a novel acquisition of mammals. In the absence of such intracortical projections, diffuse cortico-thalamo-cortical circuits may have been the main pathway allowing different cortical regions to communicate with one another, as might still be the case in reptiles. Based on results to be discussed below (Pouchelon et al. 2014; Frangeul et al. 2016; Frangeul et al. 2014), we have proposed that by providing a novel pathway to direct information to specific brain areas, supragranular intracortical projection neurons in mammals may have allowed the untethering of cortical function from input-output thalamocortical loops, and emergence of stimulus-dissociated, integrative neocortical functions.

**Development of the neocortex**

The processes allowing the emergence and functional specialization of cortical circuits start with the genesis of neurons from progenitors and extend into adulthood through experience-dependent developmental processes. Genetic, cell-intrinsic processes, and input/activity-dependent processes thus both play a role in shaping cortical circuits. While input-dependent processes classically occur at later developmental stages, activity and environment are likely to play important roles even early during differentiation, as suggested by recent, unpublished data from our laboratory showing that the bioelectric properties of neuronal progenitors affect their division modes and the type of neurons that they produce. This finding would support earlier findings in which input-dependent controls over progenitor proliferation via thalamocortical afferents oc-
curs, which could in principle contribute to area-specific differences in
cytoarchitectures and cell types (Dehay et al. 2001; Rakic, Sutier, and
Williams 1991; Zechel, Nakagawa, and Ibáñez 2016).

During embryogenesis, the diverse subtypes of neurons that form cortical
circuits are born from a pool of progenitors located deep within the brain,
underneath the developing cortex. The neurons that form the distinct lay-
ers of the neocortex are sequentially born within two main germinal zones
between E10.5 and E18.5 in the mouse: the ventricular zone (VZ) of the
dorsal pallium, which gives rise to excitatory glutamatergic neurons (Moly-
neaux et al. 2007), and a parcellated ventral pallial VZ, including the me-
dial and caudal ganglionic eminences and pre-optic area, which gives rise
to distinct subtypes of cortical inhibitory GABAergic interneurons.

Glutamatergic neurons migrate radially into the cortex from the pallial
VZ, which they populate in an inside-out manner (Fig. 3). During early
corticogenesis (until about E10.5 in mice), VZ progenitors initially
self-amplify (at this stage, they are called neuroepithelial cells), and then
begin giving rise directly to neurons (at this stage they are referred to as
"radial glia"). As corticogenesis proceeds, “direct” neurogenesis de-
creases; instead, VZ progenitors increasingly generate intermediate pro-
genitors (transit amplifying cells, also called basal intermediate progen-
itors), which accumulate between the VZ and the developing cortical plate
to form an additional germinal zone, the subventricular zone (SVZ), from
which most L2/3 neurons are thought to be born (Lui, Hansen, and Krieg-
stein 2011; Pontious et al. 2008) (Fig. 3).

Figure 3: Neurogenic sequence during corticogenesis. The neocortex is built in an inside-
out manner in which neurons born from deeply located germinal zone migrate past earli-
er-born neurons to reside in more superficial layers. Note that initially, the preplate (PP)
is split into a subplate (SP) and superficially located marginal zone (MZ) by incoming L6
neurons, such that early-born neurons are later found in L1. Direct neurogenesis from the
ventricular zone (VZ) predominates at early developmental stages, while indirect neuro-
genesis from the subventricular zone (SVZ) progressively increases during corticogenesis.
MZ: marginal zone; PP: preplate; SP: subplate. Taken from Jbabudin, 2017.
Cortical size depends on the net balance between amplifying divisions, which give rise to new progenitors, and differentiative divisions, which give rise to postmitotic neurons (Florio and Huttner 2014; Dehay and Kennedy 2007). Indirect neurogenesis increases the final number of neurons by amplifying the progenitor pool. This is thought to be a critical step in gyrification, the process through which the neocortex becomes folded in some mammals. This process allows an increase in cortical surface and neuron number within the confined volume of the cranium. The increase in cortical size is particularly striking in supragranular layers (i.e. L2/3), suggesting that cortico-cortical connections increase disproportionately compared to subcortical connections in gyrencephalic species.

An area of intense research is whether fate-restricted VZ progenitors exist (i.e. progenitors which can only give rise to a subset of cortical neurons, as is seen in subpallial proliferative zones), or whether there is a single progenitor type whose competence progresses throughout development (Franco et al. 2012; Eckler et al. 2015). This question has been difficult to investigate because it requires assessing the progeny of single progenitors with clonal resolution in vivo. Progenitors can sequentially give rise to distinct molecularly-defined neuronal cell types in vitro (Gaspard et al. 2008; Shen et al. 2006), and classical transplantation experiments in ferrets support the notion that progenitors can acquire the competence to generate normally later-born, but not earlier-born neurons (McConnell and Kaznowski 1991). Interestingly, this question of the neurogenic plasticity of cortical progenitors has not been reassessed with modern molecular tools and has only been examined in the ferret. The extent to which this principle is generalizable, and the mechanisms at play, remain thus largely unexplored.

The presence of DNA mosaicism in postmitotic neurons, likely resulting from DNA rearrangements immediately following mitosis, represents an additional potential source of neuronal functional diversity (Lodato et al. 2015). Such mosaicism may contribute to inter individual differences in cell types, circuits and behavior, and may be relevant to the broad spectrum of psychiatric disorders. If clinically relevant, diagnosis of such conditions will be challenging since causal mutations are only present in affected neurons and would not be detected by classical methods of DNA
collection, such as buccal swabs or blood samples. In a recent study to be described below, we have identified an increase in an enzyme which repairs DNA damage shortly after cell division, providing additional support for a substantial amount of mosaicism in the developing neocortex (Telley et al. 2016).

**Neocortical neuron specification and migration**

Once neurons are born, they still have to migrate and mature (i.e. develop their characteristic morphological, molecular and synaptic features). Several transcription factors control the differentiation and function of specific neuronal subpopulations of cortical neurons (Molyneaux et al. 2007), some of which I have contributed to characterize during my postdoctoral fellowship (Lai et al. 2008; Jabaudon et al. 2011). These include FEZF2 (Molyneaux et al. 2005; Chen et al. 2005) and CTIP2 (Arlotta et al. 2005) for L5B corticospinal neurons, and SATB2 for intracortical projection neurons (Alcamo et al. 2008; Britanova et al. 2008). While the initial events that control acquisition of neuron-type specific features following mitosis remain poorly characterized, we have recently shown that early neuronal differentiation is directed by a series of transcriptional waves whose sequence is critical for normal progression through development, as will now be detailed (Telley et al. 2016).

The distinct types of neurons that compose the neocortex have different connectivities but also different transcriptional signatures. While all excitatory neurons are born from progenitor cells located in the ventricular zone, below the cortex, the mechanisms that control the generation and differentiation of distinct neuronal cell types from progenitors are overall poorly understood. A main limitation in understanding these processes has been the inability to identify and isolate pure progenitor / early postmitotic cells, since the ventricular zone is a highly heterogeneous and dynamic region. To circumvent these limitations, we have developed a technology we called FlashTag that enables the isolation and visualization of neurons at the very moment they are born. Using this approach, we have identified transcriptional programs controlling neuronal differentiation (Telley et al. 2016). Upon FlashTag injections into the ventricular space, dividing progenitors are tagged with a fluorescent marker that persists in
their progeny, based on the fact that they undergo mitosis in contact with the ventricular wall (Fig. 4). Thus, nascent cohorts of simultaneously-born neurons can be labeled and isolated for transcriptional analysis using single-cell RNA sequencing (Telley et al. 2016) (Fig. 5). Using this approach, we identified and functionally characterized neuron-specific primordial transcriptional programs as they dynamically unfolded (Fig. 6). Our results revealed early transcriptional waves that instruct the sequence and pace of neuronal differentiation events, guiding newborn neurons toward their final fate. Beyond its contribution to the understanding of early neuronal differentiation events, this work potentially provides a genetic road map to be used for the reverse engineering of specific classes of cortical neurons from undifferentiated cells.

Figure 4: FlashTag (FT) labels time-locked cohorts of newborn cells during corticogenesis. (A) (Top) Schematic representation of the labeling principle. (Bottom) Pulse-labeling of isochronic mitotic cells using FT at E14.5. PH3, phospho-histone 3, an M-phase marker. (B) Isochronic cohorts of FT positive cells radially migrate from the VZ to the cortex. PAX6 and TBR2 delinate the VZ and SVZ. CP: cortical plate; Cx, cortex; IZ, intermediate zone. Taken from Telley et al., 2016.
Figure 5: Identification of newborn cortical neurons. Apical progenitors, daughter basal progenitors, and newborn neurons can be distinguished by unbiased clustering using their transcriptional signatures, obtained through single-cell RNA sequencing. Taken from Telley et al., 2016.

Figure 6: Real-time functional transcriptomics of early postmitotic neurons in vivo. (A) Genetically-identified neurons are staggered by age along a pseudotime axis, based on their transcriptional similarities. (B) Gene expression dynamics for classical proliferative (Sor2), neurogenic (Neurog2), and neuronal (Thr1) genes can be identified using this pseudotime alignment. Note for example that Neurog2 is expressed more strongly and earlier than Thr1, which enables newborn neurons to be identified at earlier time points than previously possible. QR code, http://genewbrower.unige.ch/sience2016, for access to dynamics of all transcripts. Taken from Telley et al., 2016.
Reprogramming postmitotic neurons

Manipulating gene expression in cortical progenitors can modify their competence to generate specific subtypes of neurons (Molyneaux et al. 2007), but whether neurons can be post-mitotically reprogrammed remained, until recently, unknown. To address this question, in a study published a few years ago (De la Rossa et al. 2013), we sought to reprogram L4 neurons of the mouse neocortex, which receive input connections from the thalamus, into L5B cortical output neurons. For this purpose, we used a gene delivery technique developed in the laboratory (De la Rossa and Jabaudon 2015), which enables rapid expression of select transgenes in postmitotic neurons in vivo, to ectopically express a transcription factor specific to layer 5B output neurons, Fezf2, into postnatal L4 neurons. Fezf2 was an ideal candidate to act as an identity switch, because it is both necessary and sufficient to generate L5B neurons during development. Using a combination of in vivo and ex vivo approaches, including optogenetic interrogation of the reprogrammed circuits, we demonstrated that Fezf2-expressing L4 neurons acquire the cardinal molecular, morphological, physiological, and input/output circuit properties of L5B output neurons. A remarkable feature of the reprogrammed cells was that they integrated existing circuits at the correct location (i.e. as expected for normal, naturally Fezf2-expressing cells), which we could demonstrate using cell-type specific optogenetic circuit interrogation (Fig. 7). These findings are interesting because they provided a proof-of-principle for the postnatal re-engineering of neuronal circuits in vivo, demonstrating for the first time that gene expression dynamically controls the circuit identity of cortical neurons. Furthermore, they revealed a previously unsuspected level of plasticity in postmitotic neurons, which has also been found in other cortical cell types (Rouaux and Arlotta 2013). Thus, following mitosis, neuronal fate becomes progressively restricted rather than irreversibly switched.

The cellular and molecular mechanisms controlling neuron migration from the VZ to the cortex have been well described, in particular with regard to the migration along radial glia processes and the critical role of extracellular Reelin (Tissir and Goffinet 2003). However, the cell-type specific processes controlling final laminar location remain poorly understood. From mid-corticogenesis on, there appears to be a tight rela-
Figure 7: In vivo interrogation of the circuit integration of reprogrammed neurons. L2/3 neurons are born after L4 neurons, and normally receive unidirectional projections from these cells (i.e., they do not project back to L4 neurons). In contrast, LSB neurons receive input from L2/3 cells. Using optogenetic stimulation of L2/3 cells (through in utero electroporation of channelrhodopsin, ChR2, into L2/3 cells at the time of their birth), the connectivity between L2/3 cells and L4 cells, Fez2-expressing L4 cells, and LSB cells, can be interrogated. Results show that reprogrammed Fez2-expressing L4 cells receive L2/3 input, as LSB cells normally do. Taken from De la Rosa et al, 2007.

In addition to cell-intrinsic genetic programs and extracellular molecular gradients, activity-dependent processes also control neuronal migration. This has been demonstrated for the tangential migration and differenti-
tiation of specific populations of GABAergic interneurons (De Marco García, Karayannis, and Fishell 2011). These cells can be recruited to specific target regions in an input-dependent manner, as shown both in the neocortex (De Marco García et al. 2015) and in the thalamus (Golding et al. 2014), providing an input-dependent mechanism for homeostatic regulation of circuit excitability. In the visual thalamus (i.e. dLGN), we showed that input from the retina is critical for GABAergic interneurons to migrate to their proper location and integrate into circuits (Golding et al. 2014). In this absence of this input, or upon disruption of retinal waves, which are critical for circuit assembly, interneurons mismigrate, resulting in an overall hyperexcitable circuit. This process may represent a homeostatic mechanism to compensate for decreased external inputs. Interestingly, a similar process seems to be at play in the neocortex, where we found that S1 becomes hyperexcitable upon loss of VB input (Pouchelon et al. 2014).

Compared with GABAergic interneurons, early stages of differentiation of glutamatergic excitatory neurons appear to be less dramatically affected by activity. Interestingly, cortical lamination appears to proceed largely normally in the absence of vesicular neurotransmitter release (Washbourne et al. 2002), or in the absence of input/output neocortical connectivity (Zhou et al. 2010), although the morphology and connectivity of neocortical neurons is likely to be affected. Supporting this possibility, chronic hyperpolarization of intracortical projection neurons and thalamic neurons affects axonal elongation and arborization (Mire et al. 2012; Mizuno, Hiraoo, and Tagawa 2010; Rodríguez-Tornos et al. 2016), and sensory input affects interhemispheric connectivity (Suárez et al. 2014).

Role of input in cortical neuron differentiation

Since the entry point of specific types of thalamic inputs into the cortex coincides with the presence of distinctive cytoarchitectural features (e.g. barrels in S1), a lot of effort has gone into understanding the cellular and molecular mechanisms through which input affects cortical neuron differentiation. This is a topic of particular interest in the laboratory (Fig. 8), and this question has been particularly well studied in S1 and
V1. Within these sensory areas, there is a topographical representation of the sensory periphery on the cortical surface, whereby neighbouring neurons respond to activation of neighbouring peripheral receptors, and where densely innervated regions occupy proportionally large regions of the cortical representation. This topographical layout is called somatotopy in S1, retinotopy in V1 and tonotopy in A1.

In S1, the input dependence of these maps was originally studied by lesioning sensory input pathways, such as by section of the infraorbital nerve, which conveys input from the whiskers, or by follicle cautery. These approaches consistently lead to impaired barrel patting, with shrinkage/disappearance of injured whisker representations and expansion of remaining ones (Fox and Wong 2005; Van der Loos and Woolsey 1973).

These results, however, cannot unambiguously be ascribed to purely developmental mechanisms, since injury-related processes such as axonal sprouting or neuronal death may be at play. To circumvent these limitations, pharmacological attempts have been made to manipulate sensory input, but dose-dependent effects and lack of specificity limit the inter-
pretation of these studies. More recently, manipulations of neuronal activity with cell-subtype specificity together with transcriptional analysis have enabled a better understanding of the molecular and cellular mechanisms that control the assembly of neuronal maps. These studies have shown that synaptic release of glutamate from the thalamocortical axons is required for the assembly of L4 neurons into barrels and dendritic polarization towards these axons, in particular via activation of NMDA receptors and metabotropic glutamate receptors (López-Bendito and Molnár 2003). In addition, several transcription factors, which we have contributed to identify and include Npas4, Zbtb20 function to polarize L4 dendrites towards incoming VB axons in S1 (Pouchelon et al. 2014; Wang et al. 2017; Shetty et al. 2013), and Btdb3 has a similar role in V1 (Matsui et al. 2013).

To study the role of input in cortical neuron differentiation, we developed a genetic mouse model in which VB thalamic neurons, which normally innervate L4 neurons in S1, degenerate shortly after birth, such that the latter cells do not receive their normal thalamic input (Pouchelon et al. 2014) (Fig. 9). Under these circumstances, S1L4 neurons acquired the molecular properties of L4 neurons in associative regions, i.e. in this case S2. A similar process occurs in the visual system (Chou et al. 2013; Vue et al. 2013; Pouchelon et al. 2014). Interestingly, in the case of the somatosensory cortex, deprived S1 circuits acquire S2-like features (i.e. an increase in excitatory/inhibitory ratio), suggesting that thalamic input not only affects L4 neurons but also determines downstream circuit assembly (Pouchelon et al. 2014). As already introduced in a previous chapter, these findings suggest that associative cortical identity is a ground-state feature, and that acquisition of primary cortical area circuit properties is imparted by first-order thalamic input.

Taking a step back, while our early work on the reprogramming of post-mitotic neurons described above (De la Rossa et al. 2013), in which we addressed gene-circuit relationships in the gene-to-circuit direction, here instead we manipulated neuronal circuits and assessed how this affects the genetic identity of post-synaptic target neurons. In both cases, the identity of neurons was congruently reassigned on the genetic, morphological and input-output circuit level. The Pouchelon et al. study showed that the identity of cortical neurons and the circuits they form is signi-
Figure 9: Loss of exteroceptive input leads to a respecification of L4 neurons in S1, which acquire the characteristics of L4 neurons in S2. A. Under normal conditions, L4 neurons in S1 receive VB input and L4 neurons in S2 receive Po input. Upon genetic ablation of the VB (bottom), Po input is rewired onto S1. (B) Photomicrographs showing loss of VB following genetic ablation (left, compare top and bottom), and loss of barrel patterning in S1 (right). (C) Upon acquisition of Po input, the genetic identity of L4 neurons in S1 resembles that of L4S2 neurons. Photomicrographs from Pouchelon et al., 2014.

Significantly determined by sensory input, and identified the molecular mechanisms underlying this effect. Therefore, environmental factors strongly influence neuronal gene expression and circuit formation during development, providing a path through which adverse environmental conditions could lead to abnormal gene expression and secondary circuit miswiring in neurodevelopmental disorders.

More recently, we showed that a similar process is at play within sensory thalamic nuclei, where input ablation experiments support the idea that higher-order genetic identity is a default feature, and that first-order identity is acquired in an input-dependent manner (Frangeul et al. 2016). We and others showed that in the absence of input from the retina, exteroceptive visual nucleus LGN receives input from L5B (Frangeul et al. 2016; Grant, Hoerder-Suabedissen, and Molnar 2016), a normally higher-order nucleus-destined afferent, and develops a corresponding higher-order transcriptional identity (Frangeul et al. 2016). This finding is interesting because it suggests that ascending exteroceptive and descend-
ing corticofugal inputs may thus compete to innervate thalamic nuclei (Fig. 10).

From an evolutionary perspective, the findings above support the view that neurons in primary areas and first-order nuclei/areas may have emerged from ancestral secondary/higher-order-type neurons (Slutsky, Manger, and Krubitzer 2000; Sanides 1969). We have thus proposed that first-order neurons may have been co-opted from a ground-state pool of higher-order type neurons based on their ability to convey signals generated by high-resolution body receptors because of specific metabolic, electrophysiological and connectivity features (Frangoul et al. 2016).

\[ Figure 10: \text{Rewiring of descending cortical input onto de-afferented thalamic nuclei.} \ (a) \text{Schematic of the experimental setup: Optogenetic stimulation of LSB neurons in the cortex normally activates only LP neurons, while LG neurons are not targeted. In the absence of retinal input, descending inputs now invade the LG.} \ (b) \text{Experimental results} \ (c) \text{Summary of the findings. FO: first-order nucleus, HO: higher order nucleus.} \]

**Conclusion and outlook**

The level of coordination the assembly of distinct subtypes of neurons into specialized functional circuits across space and time is staggering and raises a number of questions. What is the level of cellular diversity necessary to sustain the functions of the neocortex, and which are the features that delineate these core cell types? How do these features emerge during development and how do they vary across individuals, or in interaction with the environment? To which extent are they involved in the emergence of neurodevelopmental and neuropsychiatric disorders?

I believe that studies involving “non-clonal” model animals might contribute to better define the normal spectrum of variability in cell positioning and circuit assembly, while raising animals in more natural environments could be used to gauge the impact of experience of this process.
While these protocols will introduce natural "noise" in the system, the increase in the resolution of the tools we use to manipulate and assess neurons and circuits, including single-cell RNA sequencing, single-cell optogenetics, and targeted gene editing, will contribute to refine the read-out of these studies and provide a more truthful picture of the degrees of freedom in cortical assembly, and on the limits between normal and abnormal development.

Finally, understanding the number and nature of the independent parameters that define the configuration of the neocortex will be critical in attempts to reverse engineer developmental processes. Understanding these parameters will be important not only to define the relationship between developmental gene expression and mature neuronal function, but also to account for inter-individual variability in brain circuits and behavior in both normal and pathological settings.
Acknowledgements

I am thankful to the Professors Max Cover Foundation for honoring me and the work of my research group with this award. Past and present members of my laboratory have played a central role in this achievement. Throughout the years, we've shared passionate discussions, interventions, doubts and unexpected findings, which make it all worthwhile on a daily basis. Thank you for your commitment and resilience.

I feel deeply indebted to my scientific and clinical mentors, Beat Gähwiler, Urs Gerber, Massimo Scanziani, Teddy Landis, and Jeff Macklis. I am grateful for their generosity and trust, and for instilling a sense of confidence in my research path and professional choices. I am also thankful to my current colleagues at the Department of Basic Neuroscience, University of Geneva, for seamless and exciting scientific exchanges, and for wonderful personal interactions. I owe a lot to the Swiss National Science Foundation, which has generously supported my research throughout the years, and doubled-down when Swiss researchers transiently lost access to European funding. I feel fortunate to live in a country with a much distinguished scientific institution.

Finally, my thanks go to my wife Valérie and our daughters Pauline et Sarah. Thank you for your love, patience and support.
Bibliography


THE CLOËTTA PRIZE 2017
IS AWARDED TO
PROFESSOR

MARKUS G. MANZ

BORN IN 1967 IN STUTTGART, GERMANY
DIRECTOR OF THE DEPARTMENT OF
HAEMATOLOGY AND ONCOLOGY OF THE UNIVERSITY
HOSPITAL OF ZURICH

FOR HIS GROUND-BREAKING CONTRIBUTIONS TO
UNDERSTANDING THE DEVELOPMENT OF DENDRITIC
CELLS ON THE BASIS OF BLOOD STEM CELLS

ZÜRICH, 3RD NOVEMBER 2017

IN THE NAME OF THE FOUNDATION BOARD:

THE PRESIDENT

THE VICE PRESIDENT

MEMBER
CURRICULUM VITAE & PUBLICATIONS

Position and Work Address
- Professor/Ordinarius of Hematology University of Zürich (UZH)
- Director Hematology University Hospital Zurich (USZ)
- Director a.i. Oncology USZ
- Director Department of Hematology and Oncology USZ
- Chairman Leukemia-, Lymphoma-, Myeloma-Center USZ

Rämistrasse 100
CH-8091 Zürich
Switzerland
Ph: + 41 44 255 38 99
Fax: + 41 44 255 45 60
E-Mail: markus.manz@usz.ch
Website: http://www.haematologie-onkologie.usz.ch/Seiten/default.aspx

Personal
DOB 03.09.1967, married, 6 children

Education
1974–1987 Freie Waldorfschule, Stuttgart Uhlandshoehe, Germany
1989–1995 University of Tuebingen Medical School, Germany
1994 US Medical Licensing Examination Step II

Public Service
1987–1989 Civil service (alternative to mandatory military service)
Karl-Olga-Krankenhaus, Stuttgart, Germany
Clinical Training
1995–1999   Resident Physician, Department of Medicine, and Department of Hematology/Oncology/Immunology University of Tuebingen Medical School, Germany
2004–2006   Clinical Fellow, Department of Hematology/Oncology/Immunology University of Tuebingen Medical School, Germany

Licensure and Board Qualification
2006   Internal Medicine, Germany/European Union
2007   Hematology and Oncology, Germany/European Union
2009   Internal Medicine license recognition Switzerland (FMH)
2009   Hematology license recognition Switzerland (FMH)

Research Training
1992–1996   Thesis (Dissertation): "Tumornecrosis factor β Gen-Polymorphisms in myasthenia gravis" Department for Hematology/Transplantation Immunology, University of Tuebingen Medical School, Germany Advisor: Prof. Dr. Claudia A. Müller
1999–2002   Postdoctoral Research Fellow Department of Pathology and Developmental Biology Stanford University Medical School, USA Advisor: Prof. Dr. Irving L. Weissman
02/2007  Habilitation (Venia Legendi in Internal Medicine)  
University of Tuebingen Medical School, Germany

**Academic and Hospital Appointments**

2002–2004  Research Group Leader  
Institute for Research in Biomedicine (IRB)  
Bellinzona, Switzerland

04/2004–09/2006  Associate research group leader  
Institute for Research in Biomedicine (IRB)  
Bellinzona, Switzerland

3–9/2006  Physician, Department of Hematology/Oncology/Immunology  
University of Tuebingen Medical School, Germany  
Chairman: Prof. Dr. Lothar Kanz

08/2006  Elected «primo loco» as Director (W3) of the «Department of Cellular Therapeutics and Research» at the Essen University Medical School, Germany (refused 10/2006)

Institute for Research in Biomedicine (IRB)  
Bellinzona, Switzerland

11/2006–08/2009  Attending Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona  
Chairman: Prof. Dr. Franco Cavalli

02/2007–08/2009  Privatdozent/PD  
Medical Faculty, Eberhard-Karls-University Tuebingen, Germany

07/2008–08/2009  Vice-Director IRB, Bellinzona, Switzerland

09/2009–12/2011  Associate research group leader IRB, Bellinzona, Switzerland
09/2009–ongoing Professor/Ordinarius of Hematology at the Medical Faculty and Director Hematology at the University and University Hospital of Zürich, Switzerland

11/2010–ongoing Professor with «Promotionsrecht» at the Mathematical and Natural Sciences Faculty at the University of Zürich

01/2012–05/2017 Chairman Steering Committee Cancer Network Zürich (UZH/ETHZ)

06-2017–ongoing Steering Committee Cancer Network Zürich (UZH/ETHZ)


01/2014–ongoing Director Leukemia-, Lymphoma-, Myeloma-Center USZ

02/2014–ongoing Cancer Biology PhD Program Steering Committee Member (Life Sciences UZH/ETHZ)

2016–ongoing Secretary Swiss Society of Hematology

06/2016 Elected “primo loco” as Director (W3) Hematology and Oncology at Charite University Medicine Berlin, Germany (declined 12/2016)

07/2016–ongoing Director Department of Hematology and Oncology USZ

01/2017–ongoing Director a.i. Oncology USZ
Honors and Awards

1999  Postdoctoral Research Fellowship, Deutsche Krebshilfe (https://www.krebshilfe.de/)
2002  Swissbridge Award (http://www.swissbridge.ch)
2004  Artur-Pappenheim-Award, German Society of Hematology and Oncology (DGHO; https://www.dgho.de)
2008  San Salvatore Foundation Award (http://www.fondazionesansalvatore.ch/)
2010  Ellermann Award Hematology 2009, Swiss Society of Hematology (SGH; http://www.sgh-ssh.ch/)
2016  Otto Naegeli Award (http://wwwotto-naegeli-preis.ch/)
2017  Cloëtta Award (http://www.cloetta-foundation.ch/de/cloetta-preis/)

Professional Organizations and Societies

Swiss Society of Hematology (SGH, Secretary 2016–ongoing), Swiss Medical Association (FMH), Swiss Society for Allergology and Immunology (SSAI), German Society of Hematology and Oncology (DGHO), German Society of Internal Medicine (DGIM), European Society of Hematology (EHA, Sci Committee 2010–2013), European School of Hematology (Scientific Committee 2013–2015), American Society of Hematology (ASH), International Society of Experimental Hematology (ISEH), Henry Kunkel Society (HKS), Swiss Society of the Friends of the Weizmann Institute of Science (Board member), Charles Rodolphe Brupbacher Foundation (Sci Board), Swiss Stem Cell Network (SSCN), Cancer Network Zürich (CNZ)
Scientific Board Member
Swiss Stem Cell Network (SSCN, 2013–ongoing)
Charles Rodolphe Brupbacher Foundation (2011–ongoing)
Justus Müller Stiftung (2015–ongoing)
Swiss Soc. Friends of the Weizmann Institute of Science (2011–ongoing)
International Society of Experimental Hematology (ISEH, 2015–ongoing)
American Society of Hematology (ASH, 2015–ongoing)
Swiss Society of Hematology (SGH, 2016–ongoing)

Editorial Board Member
Blood Advances Associate Editor (2016–ongoing)

Ad hoc Editorial Referee
10 MOST IMPORTANT PUBLICATIONS


HEMATOPOIESIS – A PARADIGMATIC STEM CELL SUPPORTED ORGAN SYSTEM

Markus G. Manz

Summary

The hematopoietic system constitutes one of the largest organs in mammalian bodies. In adults, hematopoiesis is mostly confined to the bone marrow (BM) where red blood cells, platelets and white blood cells are continuously produced from rare, self-renewing hematopoietic stem cells (HSCs) and HSC-derived, highly-proliferative, increasingly lineage-restricted hematopoietic progenitor cells (HPCs). This system was shaped by evolution in a highly regulated and versatile manner, such as it is capable to respond to hematopoietic stress by increasing its output to circulation from steady state to demand-adapted production of mature hematopoietic effector cells. Adaptability, however, implies risk for instability. Indeed, with ageing, hematopoiesis becomes increasingly frail, oligo- or monoclonal hematopoiesis develops in a substantial fraction of elderly humans, and clinically relevant hematopoietic alterations may occur, which are in worst cases hematopoietic insufficiency or development of HSC-derived leukemia. Hematopoiesis stands as a paradigmatic somatic stem cell-supported organ system, which is, due to its fluid character, highly accessible and scientifically testable. Understanding intrinsic and extrinsic regulation of hematopoiesis in physiology, during hematopoietic challenge, and during the process of ageing and malignant transformation will allow to better treat hematopoietic stem and progenitor cell (HSPC) diseases, the ultimate goal in our translational research efforts. In this review, I will focus on our own scientific contributions over the last one and a half decades to understand structure and regulation of mouse and human hematopoiesis in health and disease. These, naturally, are inspired by and connected to many prior and concurrent basic and clinical research achievements from colleagues all over the world.
Introduction

Blood as a renewable and fluid organ is fascinating. This fascination finds its expression in religion, philosophy, art and medicine alike. Since the introduction of blood donation and banking, blood is the only broadly shared, cellular product or "organ", saving millions of lives. Moreover, HSC donation and transplantation for inherited or malignant disease has become routine organ-donation practice. Remarkably, this organ-transplant does not require a scalpel to be successful as HSCs can mobilize from BM to circulation and find their way "home" to bone marrow upon infusion in circulation due to selective adhesion molecule interactions. Moreover, donors re-grow HSCs upon donation, and, likely due to these facts, more volunteer donors have registered than there are recipients in need. Blood is thus connecting humans. However, it also carries critical elements of immune distinction, i.e. the white blood cells that are able to dissect self from non-self.

In this brief piece, I will focus on describing and summarizing our own work (and my fascination) on blood and bone marrow as well as immunology research and thus will mostly cite our own primary and review articles. For a broader and more balanced view on this fast evolving field, I would like to refer to the reference sections of the here cited published work.

Metrics and structural organization of bone marrow

Bone marrow (BM) accounts for 4–5% of body weight and thus exceeds other organs as brain (2%), liver (2–3%) or heart (0.5%) and lymphoid tissue (1.5%). BM generates the highest number of cells per day (4–5x10^11 cells in humans, 0.5–1.5x10^6 in mice), outnumbering cellular production of intestinal epithelium or testis. In fact, BM produces about half of its own cellular content per day and, at any given time, about 90% of total cell numbers in the organism originates from or resides in BM, although only a fraction of these cells are nucleated. In sharp contrast, HSCs only account for a very small fraction of bone marrow hematopoietic cells, i.e. 0.001–0.2% (about 28–112x10^6 in humans and 11,000–22,400 in mice) and HSPCs together account for less than 2% of BM nucleated cells, indicating impressively their replicative and burst forming potential. Table 1 and 2 summarize representative parameters of
BM function and cellularity in humans and mice (Nombela-Arrieta and Manz, 2017; Sender et al., 2016).

### Table 1. Representative parameters of BM function in humans and mice

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Humans</th>
<th>Mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total weight of BM (relative to body mass)</td>
<td>4–5 %</td>
<td>1.5–2 %</td>
</tr>
<tr>
<td>Weight in standard individual</td>
<td>3 kg</td>
<td>0.4–0.5 g</td>
</tr>
<tr>
<td>Total volume BM</td>
<td>1100 cm³–2000 cm³</td>
<td>0.35–0.4 cm³</td>
</tr>
<tr>
<td>Total volume blood</td>
<td>70–80 ml/kg</td>
<td>85–95 ml/kg</td>
</tr>
<tr>
<td>Blood volume in the BM (% of tissue volume)</td>
<td>N.D</td>
<td>15–30 %</td>
</tr>
<tr>
<td>Ratio cortical/trabecular bone</td>
<td>80:20</td>
<td>65:35</td>
</tr>
<tr>
<td>Nucleated BM cells/kg body weight</td>
<td>1.1–2.1 x 10⁹</td>
<td>1.1–1.8 x 10⁹</td>
</tr>
<tr>
<td>Total nucleated BM cells</td>
<td>0.8–1.5 x 10¹³</td>
<td>2.8–5.2 x 10⁹</td>
</tr>
<tr>
<td>Cell production/day</td>
<td>4–5 x 10¹¹</td>
<td>0.5–1.5 x 10⁹</td>
</tr>
<tr>
<td>(Total 5–7 x 10⁹ cells/kg)</td>
<td>(2–6 x 10⁹ cells/kg)</td>
<td></td>
</tr>
<tr>
<td>RBCs</td>
<td>2.2 x 10¹¹</td>
<td>0.45–0.85 x 10⁹</td>
</tr>
<tr>
<td>Platelets</td>
<td>1–1.75 x 10¹¹</td>
<td>0.16–0.7 x 10⁹</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>0.45–1.2 x 10¹¹</td>
<td>0.7–1.9 x 10⁹</td>
</tr>
<tr>
<td>Major BM cavities (% of total BM content)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lower Limbs 26–38%</td>
<td></td>
<td>Vertebra 32–32%</td>
</tr>
<tr>
<td>Vertebral 14–28%</td>
<td></td>
<td>Lower Limbs 14–20%</td>
</tr>
<tr>
<td>Pelvis 36%</td>
<td></td>
<td>Pelvis 25%</td>
</tr>
<tr>
<td>BM adipogenesis (% of BM volume)</td>
<td>50–70 %</td>
<td>1–2 % in 12 week old</td>
</tr>
<tr>
<td></td>
<td></td>
<td>18–20 % in 56 week old</td>
</tr>
<tr>
<td>(measured in proximal tibial metaphysis)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of HSCs (functional definition)</td>
<td>28–112 x 10⁹⁸</td>
<td>11200–22400</td>
</tr>
<tr>
<td>Myeloid/erythroid ratio</td>
<td>3:1</td>
<td>1.7:1–2.3:1</td>
</tr>
</tbody>
</table>
Values depicted have been in most cases obtained for, or adjusted to a reference standard individual of 70 kg for humans and 25 g for mice. Reliable estimations of total HSC numbers in humans are lacking to date. As depicted, for most parameters presented, including weight and blood cell production, the ratio of values between mouse and human species approximately falls with a range of 2500–5000. The theoretical number of HSCs for the human system provided in this table has been estimated assuming that similar ratios would apply for proportional scaling of HSC content between species.

Table adapted from: Nombela-Arrieta and Manz: Blood Advances, Feb 2017, Volume 1, Number 6

**Table 2. Cellular content of the BM as determined by flow cytometry**

<table>
<thead>
<tr>
<th>Populations</th>
<th>Humans</th>
<th>Mice</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Phenotype</td>
<td>Freq. of BMMNC (%)</td>
</tr>
<tr>
<td>HSCs</td>
<td>Lineage CD34+CD38-CD90+CD45RA-</td>
<td>0.01–0.2</td>
</tr>
<tr>
<td>Common Myeloid progenitors</td>
<td>Lineage CD34+CD38-CD123+CD45RA-</td>
<td>0.2–0.8</td>
</tr>
<tr>
<td>Common lymphoid progenitors</td>
<td>Lineage CD34+CD38-CD127-</td>
<td>0.02–0.18</td>
</tr>
<tr>
<td>Erythroid progenitors</td>
<td>CD235+CD71-</td>
<td>4–16</td>
</tr>
<tr>
<td>Granulocytes</td>
<td>CD66+</td>
<td>57–86</td>
</tr>
<tr>
<td>Megakaryocytes</td>
<td>*</td>
<td>0.05</td>
</tr>
<tr>
<td>Monocytes</td>
<td>CD14+</td>
<td>2–5.8</td>
</tr>
<tr>
<td>B cell lineage (including</td>
<td>CD19+</td>
<td>1–7</td>
</tr>
<tr>
<td>progenitors)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T lymphocytes</td>
<td>CD45-CD66+CD34+CD14-</td>
<td>8–20</td>
</tr>
<tr>
<td>Endothelial cells</td>
<td>CD45+Ter119+CD31-</td>
<td>N.D</td>
</tr>
<tr>
<td>Fibroblastic reticular</td>
<td>CD146+CD271+</td>
<td>0.02–0.08</td>
</tr>
<tr>
<td>stromal cells</td>
<td>CD146+CD31+CD140a+</td>
<td>0.03</td>
</tr>
</tbody>
</table>

55
Estimated ranges of frequencies of different hematopoietic and non-hematopoietic populations in human and mouse BM expressed as percentages of nucleated BM cells.

* Estimation based on microscopic examination of BM, not flow cytometry.

Table adapted from: Nombela-Arrieta and Manz: Blood Advances, Feb 2017, Volume 1, Number 6.

In contrast to other organs, spacial organization of BM tissues and relation of this to confined domains of blood formation is only being explored in recent years with the availability of three-dimensional tissue imaging. While mapping of BM is an ongoing effort, it already became clear that there are no clear macro-domains identifiable, but rather the BM is organized in microdomains where few hematopoietic and stromal cells (as vasculature and other mesenchymal cells) built “niches”, as HSC-niches, erythroblastic-niches or plasmacell-niches that nurture the respective cell types. Figure 1 shows a resolution of mouse BM and Figure 2 gives a schematic insight of various BM niche organizations.

**Figure 1. Three-dimensional imaging of BM**

(A) Representative stages of murine femoral bones during processing for 3D imaging. From left to right: unsectioned, sliced unprocessed and optically cleared BM slices. The last 2 images to the right correspond to an example of 3D reconstruction of the entire BM microvascular system of the femur (arteries and sinuses) using multidimensional confocal imaging of a cleared BM slice. A detailed view of the central sinus running along the longitudinal axis of the marrow is provided. (B) High-resolution 3D imaging of a reduced field of view showing sinusoidal vessels (red) and the network of perivascular bodies of CAR cells (green), forming a dense mesh through the emission of abundant cytoplasmic projectors.

Figure adapted from: Nombela-Arrieta and Manz: Blood Advances, Feb 2017, Volume 1, Number 6.
Figure 2. Structural organization of BM tissues

(A) BM stromal microarchitecture. The microarchitecture of the vascular system has been studied in detail in the mouse femoral cavity. A central artery (ca) penetrates the cavity through the nutrient canal and splits into ascending and descending branches, which run longitudinally, arborizing into smaller radial arteries that migrate toward endosteal regions. In the proximity of endosteum, arteries give rise to a dense plexus of arterioles that travel along the cortical bone area and eventually develop into venules vessels of fenestrated endothelium, termed sinusoidal. Sinusoids form a labyrinth that extends inward and merges in a big central collecting sinus (cs) that drains into the peripheral circulation (see also Figure 1). Thin periosteal arteries also penetrate the bone and merge with arteriolar vessels in endosteal regions, connecting BM and bone circulation. In trabecular bone areas, multiple smaller arteries enter the marrow cavities and give rise to sinusoidal networks along the endosteal surface of trabeculae. CXCL12–abundant fibroblastic reticular cells (CARc) extend throughout the entire cavity in the form of dense networks. Nestin-GFP+ NG2+ (mes) elongated cells run adjacent to arteries and arterioles and bundles of nonmyelinating Schwann cells (nmsc), which ensheathe adrenergic nerves. Mature osteoblasts (ob) line endosteal surfaces and are mostly derived from reticular progenitors of osteoendopoietic potential. The emergence of adipocytes (adip) takes place gradually during aging and can be abrupt and prominent in certain pathological conditions. (B) Schematic representation of cell or developmental stage-specific niches. (i) HSC niche: a number of studies have determined that HSCs are found scattered throughout BM tissues adjoining the extracellular surface of sinusoidal endothelial cells and in contact with stem cell factor–producing, LepR1 CAR cells and, in some cases, to megakaryocytes. In addition, a
minor fraction enriched in quiescent HSCs has been reported to localize in a protective niche adjacent to nonpermeable arterioles, under the regulatory influence of neighboring Nestin-GFP+Pax6 mice cells (mesenchymal cells (mes) and nonmyelinating Schwann cells (in yellow). (ii) B-cell progenitors have been suggested to sequentially migrate along different niches as they progress through maturation. Early stage pre-pro B cells are mostly found adjacent to the cell bodies of CAR cells and migrate toward IL-7-expressing CAR cells as they enter the pro B cell stage. Mature B220+ IgM B cells, in turn, move away from both stromal cell types. The latest stages of B-cell maturation occur intravascularly, within sinuoids, where the dynamic behavior of immature B cells has been visualized in vivo. In addition, early pre B cells (B220CD43) have been shown to accumulate in endosteal zones and gradually decrease in frequency toward bone-dural marrow regions. (iii) Megakaryocytes (MK) are found in close adjacency to the endothelial surface of sinuoidal vessel wall, which they traverse in the form of protrusions from which proplatelets are continuously shedded into the venous circulatory system. Red blood cell development takes place in so-called erythrophagocytic islands (EI), where erythroid precursors proliferate, enucleate, and terminally differentiate into reticulocytes around a central macrophage. 108 Plasma B cells are long-lived antibody-secreting cells that have been found in physical association to CAR cells, megakaryocytes, and eosinophils (eos). (iv) Although a significant fraction (30%) of early lymphoid progenitors (Lin-IL7-ra) has been shown to lie proximal to mature, bone-lining osteoblasts, the vast majority of phenotypically defined CLPs are in contact with IL-7-expressing CAR cells. Quiescent CD4 memory T cells are found scattered throughout the BM in contact with perisinuoidal IL-7-secreting stromal cells. Regulatory T cells (Trregs) have been reported to lodge in close proximity to the endosteum of trabecular bone.


Hierarchical Organization of Hematopoiesis

Hematopoiesis is organized in a hierarchically (Kondo et al., 2001). HSCs stand at the top of the hierarchy, are defined by their capacity to life-long self-renew, and give rise to all mature blood cells. Blood cell production from HSCs occurs in a stepwise process, where HSCs differentiate to HPCs that still have the capacity to produce all blood lineages but that have lost long-term self-renewal capacity. These HPCs then commit via highly proliferative developmental intermediates, increasingly restricted progenitor cells to end-stage differentiated blood cells. Most of these blood cells, with the exception of some lymphocytes and tissue resident phagocytic cells, are post-mitotic and can only be maintained during life by continuous active hematopoiesis from precursors.
With the development of monoclonal antibody technologies and subsequent antibody labeling of cell surface antigens, and with the development of fluorescence associated cell sorting (FACS), it became feasible to isolate rare populations of individual live cells, which subsequently could be molecularly and functionally characterized. This allowed first a population based, and now an increasingly high-resolution single cell, clonal mapping of the hematopoietic tree. A rough, principle model of hematopoiesis is depicted in Figure 3.

Figure 3. Schematic model of hematopoiesis

Schematic model of hematopoiesis depicting the hematopoietic hierarchy and the qualities of cells in the respective developmental sections. HSC, hematopoietic stem cell; HSPC = hematopoietic stem/progenitor cell; MPP = multipotent progenitor; LMPP = lympho-myeloid progenitor; CMP = common myeloid progenitor; MEP = megakaryocyte erythrocyte progenitor; GMP = granulocyte macrophage progenitor; CLP = common lymphoid progenitor; CDP = common dendritic cell progenitor; ProB = pro-B cell; ProT = pro-T cell. Figure adapted from: M.G. Mant, Swiss Medical Forum, 16(18–19); 414–418; 2016.
While there is currently agreement on the principle hierarchy, there are still open questions with regard to some of the direct clonal relationships, the existence of additional progenitor populations, as well as the essential versus possible developmental steps in steady state and during hematopoietic challenges.

We were able to characterize on a clonal level the human counterparts of the initially in mice identified myeloid committed progenitor cells (Manz et al., 2002). In addition, we were able to identify common dendritic cell progenitors in mice on a clonal level and we were able to dissect critical cytokine and signaling pathways that guide dendritic cell development and homeostasis from the earliest progenitors to steady-state mature cells (discussed below).

Why is this of relevance? Understanding the fine-tuned hematopoietic hierarchy allows to molecularly interfere, i.e. to support hematopoietic lineage development (e.g. by cytokine or small molecule application as e.g. HSPC-, erythroid-, granuloid-, thromboid-stimulating agents), or to mobilize HPSCs (e.g. chemokine receptor antagonists). Using this approach, we were able to e.g. show that thrombopoietin-agonists but not granulopoiesis stimulating agents are able to expand HSCs, at least in mice (Kovtonyuk et al., 2016b). In addition, deciphering healthy hematopoiesis helps to characterize the malignant transformed cell counterparts, and to ideally selectively interfere with their molecular machinery (e.g. using targeted kinase inhibitors). Using this approach, we were e.g. able to identify stages and pathways in aggressive transformation of chronic myeloid leukemia (Jamieson et al., 2004).

**Dendritic Cell Development from early Hematopoietic Precursor Cells**

Dendritic cells (DCs) are hematopoietic-derived, professional antigen presenting cells, key for the guidance of adaptive immunity (Merad and Manz, 2009). DCs are rare cells, comprised of multiple sub-specialized populations that are present everywhere in the body, with a relatively increased frequency at environmental contact sites as skin, lung and gut, and at sites of adaptive immune cell programming, i.e. primary and secondary lymphoid organs. DCs sample and process antigen and move from non-lymphoid to lymphoid tissues to fulfill their effector functions
(one key distinction from organ-resident macrophages). In addition, some DCs are primarily present at lymphoid organs. Figure 4 provides an overview on DC populations and turnover in mice.

**Figure 4. Mouse DC populations, location, and turnover in steady state**

DCs are distributed throughout the body. The major DC subpopulations at hematopoietic sites, environmental contact sites, filtering sites, and immune priming sites are depicted. Frequencies are given as percentage of total nucleated hematopoietic cells. Time to approximately 50% renewal is given in days (d). *Skin-draining LN; **epidermis; + present, but exact numbers not known; + present in inflammation. Professional illustration by Debra T. Duriez.

Figure adapted from: M. Merad and M.G. Marz, Blood, Volume 113, Number 15, 9 April 2009.
With the isolation of hematopoietic progenitor cells, it became possible to dissect DC developmental pathways. In *in vitro* and *in vivo* experiments, we were able to show that DCs surprisingly develop from both lymphoid and myeloid restricted progenitors (Manz et al., 2001; Chicha et al., 2004; Traver et al., 2000) and that the capacity to develop to DCs in myeloid and lymphoid populations is confined to cells expressing the receptor tyrosine kinase Flt3 (Karsunky et al., 2003). Indeed, we demonstrated that DC-development incompetent progenitors can be instructed to develop to DCs by artificially expressing and stimulating Flt3 (Onai et al., 2006). Moreover, by isolating hematopoietic progenitors on the basis of Flt3 and M-CSF receptor expression, we were able to identify and characterize committed clonal dendritic progenitor cells (CDPs) in mouse bone marrow (Onai et al., 2007), which was confirmed and extended by co-investigating groups in the field (reviewed in [Geissmann et al., 2010; Merad and Manz, 2009]). In accordance with the important role of Flt3-signaling, we found that orally applied small molecule Flt3 inhibitors generate a lymphoid tissue DC depleted phenotype within ten days of application *in vivo* (Tussiwand et al., 2005). Thus, Flt3-ligand is important in steady-state lymphoid tissue DC development and homeostasis (reviewed in [Geissmann et al., 2010; Merad and Manz, 2009; Schmäid et al., 2010]). The role of cytokines, progenitors and migration is schematically depicted in Figure 5.
MSCs produce DC progenitors, pDCs, and DCs in the BM. Flt3 ligand is a non-redundant cytokine for BM DC differentiation, although the exact role of GM-CSF and M-CSFR ligands remains to be determined. BM-derived circulating blood cells maintain, with the exception of epidermal LCs, all known steady-state DC homeostasis in lymphoid and nonlymphoid tissues. We hypothesize that progenitor cells with limited proliferation potential on Flt3 ligand and LT stimulation enter the LNs through high endothelial venules to maintain the majority of LN DCs in steady state. It is also possible that nonproliferating blood DCs follow the same route. In addition, nonlymphoid tissue DCs continuously enter the LNs through efferent lymphatics, but these represent only a minority of steady-state LN DCs. The specific contribution of proliferating DC progenitors, blood DCs, and monocytes to nonlymphoid tissue DCs in the steady state and the relative involvement of cytokines as Flt3 ligand, GM-CSF, and M-CSFR ligands remain to be addressed. In contrast to most DCs, LCs repopulate locally in the steady state either through self-renewal or through a local hematopoietic precursor that takes residence in the skin. In inflamed skin, monocytes repopulate the LC pool via a TGF-β and monocyte colony-stimulating factor receptor–dependent pathway. In the steady state, pDCs are recruited to the LN and other lymphoid organs directly from the blood and, with the exception of the liver, enter most nonlymphoid tissues only on inflammation. Whether lymphoid organ pDCs also derive from DC precursors that enter the organs remains to be determined. * Likely, but not formally proven. Professional illustration by Debra T. Dartez.

Figure adapted from: M. Merad and M.G. Mantz, Blood, Volume 113, Number 15, 9 April 2009.
We subsequently investigated which cells are relevant in Flt3-ligand production in DC homeostasis. Interestingly, we found that Flt3-ligand mediated lymphoid tissue DC maintenance is regulated in two ways, through Flt3-ligand production by non-hematopoietic cells and consumption by Flt3-expressing hematopoietic cells, as well as by antigen-mediated T-cell proliferation and Flt3-ligand secretion of these proliferating cells in adaptive immune responses, thereby stimulating local DC replenishment at lymphoid tissue inflammation sites (Saito et al., 2013). This is depicted schematically in Figure 6. Also, we found that DC progenitors from bone marrow are selectively recruited to inflamed lymph nodes via pattern-recognition receptor activation on progenitor cells (Schmid et al., 2011).

**Figure 6. Flt3L produced by proliferating T cells contribute to proliferation of cDCs and their precursors in LNs in vivo**

Model for the maintenance of lymphoid tissue DCs by Flt3 ligand. (1) In steady state, Flt3L produced by both nonhematopoietic and hematopoietic cells (mainly T cells) supports lymphoid tissue DC development. (2) During the course of a local immune response, in addition to the production of Flt3L by nonhematopoietic cells, (3) T cells are activated by antigen-presenting DCs, proliferate, and (4) produce overall more Flt3L than in steady state, and thereby (5) enhance local replenishment of lymphoid tissue DCs and their precursors.

As with other hematopoietic lineage development, mature DC subtype development is driven by both progenitor cell intrinsic permissive- and responsiveness as well as extrinsic, environmental delivered signals. Consequently, the combination of cytokine concentration and receptor expression determines whether a progenitor receives a sufficiently high signal to differentiate to a particular lineage. This can be achieved in two situations: First, if a high cytokine concentration is available to progenitors (Fig. 7A, left), they will develop irrespective of high or low expression of the respective receptor. This abundance of cytokine will occur at sites or niches where commitment and differentiation typically takes place. Second, if only small amounts of cytokine are available (Fig. 7A, right), progenitors with high receptor expression will still receive sufficient amounts of positive signal to differentiate and give rise to offspring of the corresponding lineage. However, progenitors with low receptor expression will undergo apoptosis or develop into alternative lineages if they are responsive to alternative signals. Usually, more than one cytokine will act in concert on a cell in vivo. Progenitors, which carry the potential to differentiate into two lineages, will express cytokine receptors relevant for both of these. In Fig. 7B, a cell expressing high levels of the receptor for cytokine A and low levels of the receptor for cytokine B (upper cells) and a cell expressing low receptor A and high receptor B (lower cells) are shown to be situated in an environment with overlapping concentrations of these cytokines. When both cells are located in a milieu with high concentrations of cytokine A (Fig. 7B, left), they would differentiate to lineage A, whereas they would both give offspring to cells of lineage B in a milieu with high concentrations of cytokine B (Fig. 7B, right). In the region with overlapping amounts of cytokines A and B (Fig. 7B, center), cells with high expression of receptor A would differentiate to the A lineage, whereas cells with high expression of receptor B would generate cells of lineage B (Schmid et al., 2010).
Figure 7. Hypothesis for cytokine-induced differentiation of progenitors

(A) One cytokine, one receptor scenario: If two progenitors, one with high receptor expression, the other with low receptor expression, are located near high concentrations of the respective cytokine, both cells will acquire sufficient signal to differentiate and give rise to offspring (left). If both cells are exposed to low concentrations of the cytokine, only the cell with high receptor expression will receive sufficient signaling to differentiate, while the cell with low receptor expression will not and will either undergo apoptosis or differentiate into another lineage (right) (it receives signaling through an alternate receptor (not pictured). (B) Multiple cytokines/receptors scenario. As in (A), if two progenitors, one being receptor $A_{\text{high}}$ receptor for cytokine $B$, the other receptor $A_{\text{low}}$ receptor for cytokine $B_{\text{high}}$, are exposed to high concentrations of cytokine $A$, both will differentiate into lineage $A$ (left), or conversely, if both progenitors are near very high levels of cytokine $B$, both cells will give rise to cells from lineage $B$ (right). If both progenitors are exposed to only low concentrations of both cytokine $A$ and cytokine $B$, the cell expressing receptor $A_{\text{high}}$ receptor for cytokine $B_{\text{low}}$ will preferentially differentiate into lineage $A$, while the $A_{\text{low}}$ receptor $B_{\text{high}}$ cell will differentiate into lineage $B$.

Figure adapted from: M.A. Schmid et al., Immunological Reviews 234, 2010.
Hematopoietic Stem Cell Cycling and contribution to Blood formation in Steady-State and Inflammatory Challenges

During adult steady-state hematopoiesis, more than 80% of HSCs are in a resting phase, i.e. are quiescent in G0 of cell cycle at any given time. Therefore, hematopoiesis must be supported by a small fraction of HSCs and downstream, highly proliferative HPCs. We and others thus investigate the questions a) why do we need HSC dormancy; b) which fraction of HSCs engage in hematopoiesis at any time, c) does contribution of different HSCs to hematopoiesis vary over time; d) what factors drive HSCs from quiescence to cycling and lineage commitment versus self-renewal; e) is hematopoietic and self-renewal potential of HSCs determined and correlated to HSC divisional history; and d) how does HSC proliferative history under various conditions influence functional HSC ageing, exhaustion, and possibly malignant transformation?

While others used in vivo labeling or elaborated genetic HSC labeling approaches, we modified a robust and noninvasive cellular labeling technique used largely in immunology research, i.e. labeling with 5(6)-carboxyfluorescein diacetate N-succinimidyl ester (CSFE), a cell-permeable dye that covalently binds to intracellular proteins and equally distributes to daughter cells upon cellular division to address these questions (Takizawa and Manz, 2012). This technique allows steady-state HSC transfer, bone marrow homing, in vivo tracking and high-resolution single-cell re-isolation of zero to more than five times divided live cells, and their subsequent testing in vitro and in vivo in functional assays (Kovtonyuk et al., 2016b; Pietras et al., 2016; Takizawa et al., 2017; Takizawa and Manz, 2011, 2012; Takizawa et al., 2011).

Using this approach, our first finding was that in steady-state, HSCs with equivalent life-long multi-lineage repopulation potential are contained in both frequently cycling cell populations and in quiescent cells that do not divide over 14 weeks. Our second finding was that steady-state fast-cycling HSC populations can slow down over time in steady-state serial transplantation and that HSCs with extensive proliferative history, i.e., HSCs that have gone through extended proliferation in aging or after in vivo challenge by transplantation – are prone to return to quiescence. We also showed that in vivo TLR4 challenge with Lipopolysaccharide (LPS)
recruits in vivo functional quiescent HSCs into proliferation and self-renewal with unbiased lineage repopulation capacity (Takizawa et al., 2011). Moreover, our mathematical simulation reveals that HSCs with different cycling activity can be contained in one HSC population with relatively broad cycling variation and that, on average, HSCs divide 18x during a 2-yr lifespan of a laboratory mouse (Takizawa and Manz, 2011; Takizawa et al., 2011).

Based on these results, we proposed a dynamically fluctuating HSC cycling model in steady-state, where the turnover of all HSCs would naturally be similar at end of life. This would assure protection of the dormant HSC fraction from cell cycle damaging events, and would allow at the same time overall homogenous use of HSC resources during life. This model is in line with a linear correlation of telomere shortening in human HSCs with aging. Also, it would be in line with an increased risk for the whole HSC population to accumulate genetic events, promoting clonal HSC diseases as myelodysplasia and myeloid leukemia in the aged population.

Steady-state cycling differences of HSCs at any given time in this model would reflect the broad variation of possibilities, but not a static separation of HSCs in distinct classes with different divisional kinetics. Increased cycling of most HSC during hematopoietic challenges via external cues might have developed as an advantage to recruit dormant HSCs in order to better cope with blood cell demand for the necessary time. Broad activation, however, also poses a risk to loose HSCs due to genetic vulnerability and differentiation. Thus, a mechanism to "drive" HSCs to quiescence that increases strength with frequency of total HSC divisions needed to be established. This might be achieved by down-modulation of sensitivity to external stimulation and upregulation of sensitivity to quiescence signals. Indeed, we observed that phenotypically defined HSC populations with extensive proliferative history, i.e., HSCs from aged mice and HSCs that have divided massively after transplantation, subsequently increase quiescence in steady-state environments, likely as an effort to prevent HSC exhaustion (Takizawa and Manz, 2011; Takizawa et al., 2011). Figure 8 shows a graph that illustrates the above-discussed findings.
HSC repetitively fluctuate in steady-state from quiescence to activation and blood production. At end of life, all HSCs have gone through about the same frequency of divisions. Upon challenge as e.g. massive infection, HSC are recruited from dormancy and contribute to blood formation for the necessary time, to subsequently re-establish fluctuation from quiescence to activation in steady-state.

Figure adapted from: H. Takizawa et al., J Exp Med. 2011; 208(2):273-84
To dissect effects of cytokines, chemokine receptor antagonists and direct pathogen-derived stimuli on HSC cycling and function, we further tested *in vitro* and *in vivo* stimulation with thrombopoietin-analoga, granulocyte colony stimulating factor (G-CSF), Flt3-ligand, interleukine-1 (IL-1), and with LPS and life gram-negative bacterial infection (Kovtunyuk et al., 2016b; Pietras et al., 2016; Takizawa and Manz, 2017).

We found that thrombopoietin receptor stimulation on HSCs leads to HSC cycling and expansion without loss of self-renewal capacity (Kovtunyuk et al., 2016b). In contrast, Chronic interleukin-1 exposure drives HSCs towards myeloid differentiation at the expense of self-renewal (Pietras et al., 2016), while G-CSF, Flt3-ligand and CXCR4 antagonists did not affect HSC cycling and potential (Kovtunyuk et al., 2016b). Given the enhancement of multi-lineage regeneration by thrombopoietin-receptor agonists, possibly via cycling and re-expansion of human HSCs in aplastic anemia, we speculate that these also might be tested in clinical settings as an add-on to conditioning chemotherapy before allogeneic HSC transplantation in order to reduce endogenous HSCs. Furthermore, we speculate that, if the thrombopoietin receptor is expressed on malignant counterparts of HSCs, these could also be targeted by thrombopoietin-receptor agonist chemosensitization (Kovtunyuk et al., 2016b).

We also found that self-renewing HSCs directly sense gram-negative bacterial infection through Toll-like receptor 4 (TLR4) activation, which leads to impaired function via proliferative stress. However, this could be prevented by pharmacological blockage of the TLR4-TRIF-ROS-p38 axis (Takizawa et al., 2017). Interestingly, we previously contributed to a collaborative project where we found with our colleagues that very low concentrations of microbial antigens and TLR ligands derived from the intestinal microbiome, well below the threshold required for induction of adaptive immunity, sets the bone marrow myeloid cell pool size (Balmer et al., 2014). Whether inhibition of this pathway as a means of preemptive medicine is able to prevent or delay aging-associated and inflammation-associated HSC defects and malignant transformation will need to be determined in future studies (Kovtunyuk et al., 2016a; Luis et al., 2016; Takizawa et al., 2012; Takizawa et al., 2017; Takizawa and Manz, 2017). Figure 9 shows the related cover of the Cell Stem Cell issue, describing our findings in a cartoon in front of our geographical region.
Figure 9. HSCs in action under inflammation

The cover of Cell Stem Cell describes our findings in a cartoon in front of our geographical region. Designed by Latinya Kozhymuk, Ph.D., member of our laboratory and co-author of the related manuscript. Cell Stem Cell, August 3, 2017
Regulation of Emergency Granulopoiesis

Steady-state hematopoiesis is switched to infection-induced emergency hematopoiesis following detection of systemically disseminated microbial pathogens (e.g., viruses, bacteria, fungi, and parasite). A prototypic and clinically well known response is emergency granulopoiesis, with increase of granulocytes and shift to immature forms in peripheral blood, and release and massively increased production of granulocytes in BM upon lack of local infectious control and systemic spread of bacteria, i.e. bacteremia and sepsis (Figure 10).

Figure 10. Local versus systemic bacterial infection

a) During a localized bacterial infection in an immunocompetent individual, several pre-existing antimicrobial effector mechanisms contain bacterial pathogens locally. In most cases, this leads to a rapid resolution of the infection, thereby preventing bacterial dissemination. As a consequence, bone marrow granulopoiesis is unaffected and does not differ from steady-state conditions. b) By contrast, in the setting of severe bacterial infection that overwhelms first-line defense mechanisms, bacterial dissemination occurs and neutrophils are consumed in large quantities, with pre-existing neutrophil pools being used. To counterbalance neutrophil depletion and to provide a supply of urgently needed neutrophils to combat systemic bacterial spread, a haematopoietic response programme termed 'emergency granulopoiesis' is initiated, which is characterized by the large-scale de novo generation of neutrophils from myeloid progenitors in the bone marrow. The expansion of bone marrow granulopoiesis is paralleled by a decrease in bone marrow lymphopoiesis.

Figure adapted from: M.G. Manz and S. Boettcher, Nat Rev Immunol., Vol. 14, May 2014.
How and by which cells sensing of systemic bacterial spread is accomplished, and how this sensing is translated into appropriately, life-saving granulocyte production and subsequent decrease of it upon clearance of infection, was poorly understood. We thus addressed the fundamental question of which cell types act as primary sensors of bacterial dissemination during severe infection and consequently induce the switch from steady-state to demand adapted emergency granulopoiesis.

We approached this by in vivo elimination of sensors (TLR4) or downstream signaling molecules (MyD88) in hematopoietic and non-hematopoietic cells using genetic Cre recombinase-mediated tissue-specific ablation approaches. Against our expectations, we found that pathogen sensing by both immature HSPCs and mature hematopoietic cells, including macrophages, is dispensable for the acute process of emergency granulopoiesis. In contrast, we discovered that endothelial cells (ECs) express sensors and, upon ligation of those, are the major producers of G-CSF, which then induces emergency granulopoiesis (Boettcher et al., 2014; Boettcher et al., 2012). Our findings reveal a sophisticated degree of functional interplay between the vascular, the hematopoietic, and the immune systems, which have a common developmental root and might thus be understood as one functional organ. Indeed, ECs are ideally positioned to mark the threshold of local vs systemic infection, and using ECs as safeguards seems a very plausible, danger-adapted defense strategy established in evolution (Boettcher and Manz, 2016, 2017; Manz and Boettcher, 2014). Figure 11 summarizes our proposal for a model of infection-driven emergency hematopoiesis, integrating additional findings from our and other research groups in the field.
Figure 11. Integrated model of emergency hematopoiesis

Multiple distinct and most likely complementary pathways exist and these [284TDSDIF] govern how pathogen-derived signals are detected and translated into emergency hematopoiesis. Of note, the order of mentioning individual pathways does not indicate their importance. (1) Interferon-γ (IFNγ) released from CD8+ cytotoxic T lymphocytes (CTLs) promotes emergency hematopoiesis by stimulating perivascular mesenchymal stromal cells (MSCs) to secrete interleukin-6 (IL-6) as well as by directly acting on granulocyte-macrophage progenitors (GMPs), thereby favoring a monocytic lineage fate. (2) IFNγ can also directly induce hematopoietic stem cell (HSC) cycling and recruit quiescent HSCs into the cell cycle. (3) Pathogen-associated molecular patterns (PAMPs) are also able to stimulate HSC proliferation but it remains to be determined whether it is accomplished directly or indirectly. (4) Reactive oxygen species (ROS) released by bone marrow Gr1+ myeloid cells (including monocytes and neutrophils) during Toll-like receptor (TLR) agonist stimulation enhance upstream myeloid precursor proliferation and differentiation. (5) CXCL12-abundant reticular (CAR) cells are a major source of IL-6 that is of importance to sustain emergency granulopoiesis (S.B. and M.G.M., unpublished data). (6) Granulocyte-colony-stimulating factor (G-CSF) secreted from predominantly arteriolar endothelial cells (AECs) following lipopolysaccharide (LPS) recognition in an MYD88-dependent manner stimulates emergency granulopoiesis. (7) Direct PAMP recognition by mainly short-term HSCs (ST-HSCs) and multipotent progenitors (MPPs) leads to IL-6 secretion, which acts in an autocrine/paracrine manner to stimulate emergency hematopoiesis. Abbreviations: CMP, common myeloid progenitor; LT, long-term.

Figure adapted from: S. Boettcher and M.G. Manz, Trends in Immunology, May 2017, Vol 38, No. 5.
Future studies will need to determine if there are pathogen-specific differences in the activated emergency hematopoietic pathways, what factors determine the threshold for induction of emergency hematopoiesis, what is the contribution of HSC activation versus myeloid progenitor activation to the overall magnitude of emergency hematopoiesis? Is HSC activation during this process a physiologic response or indicative of a failure to control infection, what are the long-term hematopoietic and immunological consequences and the possible underlying molecular mechanisms of chronic infection and inflammation, and what is the molecular mechanism by which chronic infection/inflammation increases the risk for developing hematologic malignancies (Boettcher and Manz, 2017)?

**In vivo model Systems to study human Hematopoiesis in Health and Disease**

Knowledge on human hematopoiesis and immunology is predominantly gained by clinical observation, cautious, safety-oriented in vivo experimentation, and in vitro surrogate assays (Manz, 2007). Progress in clinical research is mostly slow, and rigorous scientific proof is frequently impossible. Given appropriate ethical consideration, most societies agree on research involving worms, flies, and small vertebrates as mice. Indeed, laboratory mice have become the main model for in vivo basic and applied biomedical science. However, approximately 65 million years of divergence in human and mouse evolution have shaped these two species that differ substantially in size, lifespan, reproductive activity, and exposure to environmental challenges, e.g., species-specific infectious agents that coevolved. Concerning hematology and immunology, many similarities exist, however, mice are not men and some loss in translation of achievements between these two species is observed. Humanized mice, i.e. mice that carry human molecular or tissue elements have been generated over the last few decades with the intention to fill this gap, i.e. to model human physiology and pathology in accessible ways in vivo. Achievements in generating human hematopoietic mice are summarized in recent reviews by us and colleagues working in the field (Legrand et al., 2009; Manz, 2007; Rongvaux et al., 2013; Shultz et al., 2007; Theocharides et al., 2016; Macchiarini et al., 2005).
In brief, we hypothesized that transplantation of human HSCs into the liver, i.e. a hematopoietic active organ, of newborn T cell, B cell and NK cell deficient mice (Rag2−/−-gamma common chain−/−) would lead to human hematopoietic cell development and replacement of lacking mouse components. Indeed, the expanding organism provides a suitable environment for high-level human HSC engraftment and lymphocyte development (Traggiai et al., 2004). We, together with collaborators, could show that human-specific lymphotropic infections with Epstein Barr and Human Immunodeficiency Virus (Baenziger et al., 2006; Cocco et al., 2008; Neagu et al., 2009; Traggiai et al., 2004) are possible and some elements of human disease develop. However, due to insufficient adaptive immune cell education and insufficient cross-reactivity of growth factors in the xenogeneic environment, human adaptive immune reactions are weak, human HSCs are not sufficiently maintained over time, and human myeloid cells developed only at very low numbers and did not populate tissues sufficiently. In order to overcome the limitations of insufficient cytokine cross-reactivity and rejection of human cells via the innate macrophage response, we, in collaboration with Richard Flavell’s laboratory at Yale and Regeneron, a company specialized in genetic engineering, generated mice that express human HSC and myeloid cell supporting growth factors under the regulatory element of the mouse genes (Strowig et al., 2011; Takizawa and Manz, 2007). Furthermore, we expressed a human SIRPα transgene on the mouse background to avoid human cell elimination via mouse phagocytic cells (Das et al., 2016; Rathinam et al., 2011; Rongvaux et al., 2014; Rongvaux et al., 2011; Strowig et al., 2011; Willinger et al., 2011). Indeed all engineering steps led to stepwise improvement of human cell engraftment and quality of human hematopoiesis and the combination of human growth factors in mice led to human cell development and distribution that closely resembles distribution in humans (Rongvaux et al., 2014; Theocharides et al., 2016). We now use these humanized mice to model specific human diseases (Figure 12).
Using these models for human malignancies, we were able to demonstrate a) contribution of human myeloid cells to human melanoma growth (Rongvaux et al., 2014), b) dependence of human favorable-risk AML on macrophage colony-stimulating factor (M-CSF) (Ellegast et al., 2016), and dependence of human clonal plasma cell disease on cytokine combinations including IL-6 (Das et al., 2016). We are hopeful that human-hematolymphoid system mice will further be useful for pre-clinically, predictive testing of therapies and thus accelerate development of new successful therapeutic approaches.
Hematopoietic Stem Cells, (Inflamm-)Ageing and Clonal Dominance

With increasing age, HSCs get more numerous (about twofold increased, biologically defined HSCs in aged mice compared to young adult mice), however, their differentiation is biased towards myelopoiesis and their overall self-renewal and output capacity is reduced (Kovtonyk et al., 2016a). While most of the data on ageing of HSCs is derived from mice, similar observations are made in humans. Biology of aged HSCs, similar as biology of other cells in other tissues, is driven by both cell-intrinsic as well as cell-extrinsic factors. An overarching theme is the association of ageing and inflammatory signatures, even in a steady-state situation. Indeed, by analyzing BM gene transcription in hematopoietic and non-hematopoietic cells and by measuring expression of bone marrow protein presence in ageing and in inflamed situations, a high level of concordance emerges (unpublished data). We and colleagues in this research field are thus referring to “inflamm-ageing” of hematopoiesis, and we summarized potential hallmarks of this process (Kovtonyk et al., 2016a) (Figure 13).

Figure 13. Potential hallmarks of inflamm-ageing

In this context, it is highly interesting that the occurrence of HSC neoplasia as AML, MDS and MPN are associated with repetitive infection and inflammatory diseases, and, even more so, with ageing. Surprisingly, benchmark studies in humans without hematopoietic diseases demonstrated during the last years, that clonal dominance of genetically altered hematopoiesis is a frequent event in the ageing population (more than 10% in the over 70 years old) (Xie et al., 2014; Genovese et al., 2014; Jaiswal et al., 2014). Presence of these clonalities was coined as “clonal hematopoiesis of indetermined potential” (CHiP). Indeed, the genetic alterations that cause clonal dominance are frequently affecting the same genes that have been shown before to be associated or cause AML, MDS and MPN. However, only a small fraction (1–2% per year) of individuals with CHiP develop these diseases. Thus, in this sense, CHiP shows similarities to other clonal, non-disease defining alterations in the hematolymphoid system as monoclonal B cell lymphocytosis (MBL) and monoclonal gammopathy of unknown significance (MGUS) (Steenstra et al., 2015). Again, one could speculate that what we observe here in the
hematopoietic system is similarly occurring in other organ systems without thus far being noticed. While occurrence of genetic CHiP-driver alterations might follow a simple stochastic rule with numbers of cell divisions, we speculate that inflammatory drive in addition might modulate and enhance risk (Takizawa et al., 2012). This is depicted in Figure 14.

Figure 14. Hypothetical model for inflammation-enhanced malignant transformation in early hematopoiesis

A key task is now to understand reasons for progression of CHiP to neoplasia, identify individuals at risk, and develop means to interfere clinically. To this end, we work on a project where we evaluate HSCs and hematopoiesis from one “source” under different environmental conditions. We analyze long-term surviving HSC recipients and their HSC donors for their HSC status on a population and clonal level, and we corre-
The 3 principle outcomes of HSC divisions are self-renewal, differentiation, and death. The balance between these 3 cell fates is closely regulated to ensure balanced blood cell production over the lifetime of an individual. With increased proliferative history in the HSC compartment, the probability of acquiring genetic alterations ("hits") in HSCs increases, but efficient counteractive mechanisms (eg, apoptosis, DNA repair) have evolved to remove or correct genetically altered HSCs from the pool (top). It can be hypothesized that under chronic or repetitive inflammation the likelihood of genetic hit acquisition and subsequent accumulation in HSC is increased by two major mechanisms: First, accelerated HSC cycling and self-renewal enhances the statistical probability of acquiring mutations during DNA replication. Second, genetically altered HSC clones are rescued by signals delivered from the inflammatory environment. Persistent and aberrant self-renewal of the respective HSC clone might enhance occurrence of further genetic hits, eventually, resulting in the development of HSC neoplasia, for example, acute myeloid leukemia/myelodysplastic syndrome (AML/MDS, bottom).

Figure adapted from: H. Takizawa et al., Blood, 29 March 2012, Volume 119, Number 13.
late inflammation/infection, proliferative history and function of HSCs with occurrence and progression of CHiP. We are positive that this unique long-term read-out (in some cases more than 30 years) will shed light on the problem, covering both basic and clinically relevant aspects.

Conclusions and Perspective

Since the beginning of my clinical and scientific career more than twenty years ago, gain of knowledge in molecular understanding of benign and malignant hematology and knowledge-driven capacity to clinically interfere and control or even cure diseases lead to enormous leaps forward. Indeed, few treatment approaches are still the same as they have been then, and because of these developments, being a patient today is in an ever-growing fraction more bearable than before. Further, many basic principles observed in easy to access and to test hematopoietic cells and diseases and respective new treatment approaches have been extended and applied to other organ systems. I am motivated by better care through science and humanities and I am hopeful to contribute with our research on hematopoiesis, hemato-immunology, and hematopoietic malignancies pieces of understanding and insight, ultimately adding to maintenance of well-being of an ageing population and to re-gaining health of patients.
Acknowledgements

I would like to express my deep gratitude to the Professor Max Chaetla Foundation for honoring our work by this prestigious award. I accept it as an individual, supported by my inspiring mentors Lothar Kanz, Irving Weissman, Franco Cavalli, Antonio Lanzavecchia, and Hans Hengartner, my enthusiastic colleagues and friends, as well as my eager past and current lab-members and clinical fellows who did and do the work and who will accelerate future medical progress for our patients. I am indebted to the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, the Swiss National Science Foundation, the Swiss Cancer League, the US National Institute of Health, the Bill and Melinda Gates Foundation, the Institute for Research in Biomedicine and the University and University Hospital of Zurich for trusting in our aims and for funding our research. Finally, my thank goes to my late father, a passionate teacher, and to my optimistic, humorous wife and our children.
REFERENCES


Die Stiftung Prof. Dr. Max Cloëtta

Die Stiftung Prof. Dr. Max Cloëtta wurde am 27. September 1973 in Zürich von Dr. Antoine Cloëtta zu Ehren seines Vaters Prof. Dr. Max Cloëtta errichtet.

In Absatz 1 von Art. 3 der Stiftungsurkunde wird der Zweck der Stiftung wie folgt umschrieben:

«Die Stiftung bezweckt:
  a) die Unterstützung und Förderung der medizinischen Forschung sowie der damit verbundenen naturwissenschaftlichen Hilfswissenschaften in der Schweiz;
  b) die Schaffung und jährliche Verleihung eines Cloëtta-Preises

zur Auszeichnung schweizerischer und ausländischer Persönlichkeiten, die sich in besonderer Weise um bestimmte Gebiete der medizinischen Forschung verdient gemacht haben.»
### Stiftungsrat

Im Jahr 2017 setzt sich der Stiftungsrat wie folgt zusammen:

<table>
<thead>
<tr>
<th>Name</th>
<th>Universität / Institution</th>
<th>Funktion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prof. Dr. Adriano Fontana</strong></td>
<td>Universität Zürich Hertie-Senior Forschungsprofessor</td>
<td>Präsident des Stiftungsrates und des Medizinischen Ausschusses</td>
</tr>
<tr>
<td><strong>Dr. Hans Bollmann</strong></td>
<td>Rechtsanwalt, Zürich</td>
<td>Vizepräsident des Stiftungsrates</td>
</tr>
<tr>
<td><strong>Prof. Dr. Gabriela Finke</strong></td>
<td>Universitäts-Kinderklinik Basel Lederin Forschungs-</td>
<td>Mitglied des Stiftungsrates</td>
</tr>
<tr>
<td></td>
<td>abteilung</td>
<td></td>
</tr>
<tr>
<td><strong>Prof. Dr. Hugues Ahriel</strong></td>
<td>Universität Bern Institut für klinische Forschung</td>
<td>Mitglied des Stiftungsrates</td>
</tr>
<tr>
<td><strong>Prof. Dr. Fritjof Helmchen</strong></td>
<td>Universität Zürich Co-Direktor Institut für Hirnforschung</td>
<td>Mitglied des Stiftungsrates</td>
</tr>
<tr>
<td><strong>Peter Ochsner</strong></td>
<td>Verwaltungsrat BCC</td>
<td>Mitglied des Stiftungsrates</td>
</tr>
<tr>
<td><strong>Prof. Dr. Walter Reith</strong></td>
<td>Universität Genf Institut für Pathologie und Immunologie</td>
<td>Mitglied des Stiftungsrates</td>
</tr>
<tr>
<td><strong>Hans Georg Syz-Witmer</strong></td>
<td>Maerki Baumann &amp; Co. AG, Zürich</td>
<td>Mitglied des Stiftungsrates</td>
</tr>
<tr>
<td><strong>Prof. Dr. Bernard Thorens</strong></td>
<td>Universität Lausanne Zentrum für integrative Genforschung</td>
<td>Mitglied des Stiftungsrates</td>
</tr>
</tbody>
</table>

*Mitglieder des Medizinischen Ausschusses
**Mitglieder des Verwaltungsrats-Ausschusses
Übersicht über die bisher erschienenen Publikationen
der Schriftenreihe Stiftung Professor Dr. Max Cloëtta

Heft Nr. 1 (6. Auflage 2000):
Vorwort von Bundesrätin Ruth Dreifuss
Biographie von Professor Dr. Max Cloëtta
Biographie von Dr. Antoine Cloëtta
Übersicht über die Stiftung Professor Dr. Max Cloëtta
Ehrentafel der Preisträger
Organe der Stiftung

Heft Nr. 2:
Preisverleihung 1974
Festvortrag des Preisträgers Dr. med. Urs A. Meyer:
«Klinische Pharmakologie—eine Herausforderung für
interdisziplinäre Zusammenarbeit»

Heft Nr. 3:
Preisverleihung 1975
Festvortrag des Preisträgers Dr. med. Hans Bürgi:
«Die Bekämpfung des Kropfes in der Schweiz. Ein Beispiel der
Zusammenarbeit zwischen Grundlagenwissenschaftern,
Kliniken und Behörden»

Heft Nr. 4:
Cérémonie de remise du prix 1976
Exposé du Dr. Rui C. de Sousa, sur le thème:
«La membrane cellulaire: une frontière entre deux mondes»

Heft Nr. 5:
Preisverleihung 1977
Festvortrag des Preisträgers Professor Dr. Franz Oesch:
«Chemisch ausgelöste Krebsentstehung»
Heft Nr. 6:
Preisverleihung 1978
Festvortrag des Preisträgers Dr. Susumu Tonegawa:
«Cloning of Immunoglobulin Genes»

Heft Nr. 7:
Preisverleihung 1979
Festvorträge der beiden Preisträger
Professor Dr. Theodor Koller:
«Die strukturelle Organisation des genetischen Apparates höherer Organismen»
Professor Dr. Jean-Pierre Krähenbuehl:
«Hormonal Control of the Differentiation of the Mammary Gland»

Heft Nr. 8:
Preisverleihung 1980
Festvorträge der beiden Preisträger
Professor Dr. Edward W. Flückiger:
«Neue Aspekte der Mutterkorn-Pharmakologie»
PD Dr. Albert Burger:
«Ein Vierteljahrhundert nach Entdeckung des aktivsten Schilddrüsenhormons (Trijodothyronin)»

Heft Nr. 9:
Preisverleihung 1981
Festvorträge der beiden Preisträger
Professor Dr. Rolf Zinkernagel:
«Selbst-Erkennung in der Immunologie»
Professor Dr. Peter A. Cerutti:
«A role for active oxygen species in human carcinogenesis?»
Heft Nr. 10:
Preisverleihung 1982
Festvorträge der beiden Preisträger
PD Dr. Jürgen Zapf:
«Wachstum und Wachstumsstörungen: ein gemeinsames Forschungsziel der klinischen und experimentellen Endokrinologie»
PD Dr. Jean-Michel Dayer:
«Le monocyte-macrophage: un pivot entre le système immum et le tissu conjonctif dans le processus inflammatoire de l’arthrite rhumatoïde»

Heft Nr. 11:
Preisverleihung 1983
Festvorträge der beiden Preisträger
Professor Dr. Peter Böhlen:
«Peptides and Proteins as messengers in the communication between cells and organs»
PD Dr. Claes B. Wollheim:
«Regulation of insulin release by intracellular calcium»

Heft Nr. 12:
Preisverleihung 1984
Festvorträge der beiden Preisträger
Frau Professor Dr. Heidi Diggelmann:
«Beiträge der Retroviren zur Aufklärung grundlegender biologischer Prozesse»
Professor Dr. Jean-François Borel:
«Entwicklung und Bedeutung des Ciclosporins»

Heft Nr. 13
Preisverleihung 1985
Festvorträge der beiden Preisträger
Professor Dr. Hans Thoenen:
«Entwicklungsgenetik: von der deskriptiven Analyse zum molekularen Verständnis»
Dr. Roberto Montesiano:
«Cell-Extracellular Matrix Interactions in Organogenesis»
Heft Nr. 14:
Preisverleihung 1986
Festvorträge der beiden Preisträger
Professor Dr. Ueli Schibler:
«Mechanismen der gewebespezifischen Regulation von Genen»
Professor Dr. Walter Schaffner:
«Enhancer-Sequenzen und die Regulation der Gen-Transkription»

Heft Nr. 15
Preisverleihung 1987
Festvorträge der beiden Preisträger
Professor Dr. Jacques Louis:
«Rôle des lymphocytes T spécifiques sur l’évolution des lésions induites par leishmania major, un parasite vivant dans les macrophages de leur hôte»
Professor Dr. Joachim H. Seelig:
«Magnetische Resonanz-ein «magnetisches Auge» zur Untersuchung der Lebensvorgänge in vivo»

Heft Nr. 16:
Preisverleihung 1988
Festvorträge der beiden Preisträger
Professor Dr. Jean-Dominique Vassalli:
«Protéolyse et migrations cellulaires: Multiples facettes du contrôle d’une cascade enzymatique»
PD Dr. Hans Hengartner:
«Über die immunologische Toleranz»

Heft Nr. 17:
Preisverleihung 1989
Festvorträge der beiden Preisträger
Professor Dr. Heini Murter:
«Parathormon: Auf dem Weg zum Verständnis seiner Wirkung im proximalen Tubulus»
Dr. Hugh Robson MacDonald:
«Selection of the T Cell Antigen Receptor Repertoire during Development»
Heft Nr. 18:
Preisverleihung 1990
Festvorträge der beiden Preisträger
Professor Dr. Martin E. Schwab:
«Entwicklung, Stabilisierung und Regeneration von Faserverbindungen in Gehirn und Rückenmark: Die Rolle von Nervenwachstums-Hemmstoffen»
Professor Dr. Denis Monard:
«Protéases et inhibiteurs extracellulaires dans le système nerveux»

Heft Nr. 19:
Preisverleihung 1991
Festvorträge der beiden Preisträger
PD Dr. Peter J. Meier-Abt:
«Die Ausscheidungsfunktionen der Leber: Rolle von Membrantransport-Systemen»
PD Dr. Jacques Philippe:
«Structure and pancreatic expression of the insulin and glucagon genes»

Heft Nr. 20:
Preisverleihung 1992
Festvorträge der beiden Preisträger
PD Dr. Leena Kaarina Bruckner-Tuderman:
«Molecular Pathology of the Epidermal-Dermal Interface in Skin»
Professor Dr. Jürg Tschopp:
«Das Phänomen der von Lymphozyten vermittelten Zellyse»

Heft Nr. 21:
Preisverleihung 1993
Festvorträge der drei Preisträger
Dr. Paolo Meda:
«Cell-to-cell Communication and Pancreas Secretion»
Professor Dr. Adriano Fontana:
«Transforming Growth Factor Beta 2, ein von Tumorzellen gebildetes Zytokin mit immunparalysierender Wirkung»
Professor Dr. Michel Aguet:
«Neue Erkenntnisse zur Biologie und Molekularbiologie der Interferone»

Heft Nr. 22:
Preisverleihung 1994
Festvorträge der beiden Preisträger
Professor Dr. rer. nat. Hans Rudolf Brenner:
«Die Regulation der Expression synaptischer Transmitter-Rezeptoren während der Synapsenbildung»
Daniel Pablo Lew, Professeur ordinaire de médecine:
«Signal Transduction and Ion Channels Involved in the Activation of Human Neutrophils»

Heft Nr. 23:
Preisverleihung 1995
Festvorträge der beiden Preisträger
Professor Dr. Jürg Reichen:
«Die sinusoidale Endothelzelle und Leberfunktion»
Dr. George Thomas jr.:
«The p70^5^6 Signal Transduction Pathway, S6, Phosphorylation and Translational Control»

Heft Nr. 24:
Preisverleihung 1996
Festvorträge der beiden Preisträger
Dr. Lukas C. Kühn:
«Molekulare Mechanismen zur Steuerung des Eisenstoffwechsels»
Professor Dr. Peter Sonderegger:
«Wegweiser- und Sensormoleküle beim gezielten Wachstum der Nervenzellausläufer»
Heft Nr. 25:
Preisverleihung 1997
Festvorträge der beiden Preisträger
Dr. Gérard Waerber:
«Métabolisme moléculaire de la cellule insulino-sécrétrice»
Professor Dr. Denis Duboule:
«Genetic control of limb morphogenesis and evolution»

Heft Nr. 26:
Preisverleihung 1998
Festvorträge der beiden Preisträger
Professor Dr. Adriano Aguzzi:
«Pathophysiologie der Prionen-Krankheiten»
Professor Dr. Primus E. Mullis:
«Short stature: from the growth hormone axis to the Development of the pituitary gland»

Heft Nr. 27:
Preisverleihung 1999
Festvorträge der beiden Preisträger
Professor Dr. Clemens A. Dahinden:
«Pathophysiologie der allergischen Entzündung»
Professor Dr. Antonio Lanzavecchia:
«Deciphering the signals that regulate T cell mediated immunity»

Heft Nr. 28:
Preisverleihung 2000
Festvorträge der beiden Preisträger
Professor Dr. Giuseppe Pantaleo:
«Mechanisms of human immunodeficiency virus (HIV) escape from the immune response»
Dr. Brian A. Hemmings:
«Protein kinase B (PKB/Akt)—a common element in multiple signaling pathways involved in insulin signaling, cell survival and cancer»
Heft Nr. 29:
Preisverleihung 2001
Festbeiträge der beiden Preisträger
Professor Dr. Isabel Roditi:
«The surface coat of african trypanosomes»
Dr. Thierry Calandra:
«Innate immune responses to bacterial infections: a paradigm for exploring the pathogenesis of septic shock»

Heft Nr. 30:
Preisverleihung 2002
Festbeiträge der beiden Preisträger
Professor Dr. Bernard Thorens:
«Impaired Glucose Sensing as Initiator of Metabolic Dysfunctions»
Professor Dr. Andrea Superti-Furga:
«Molecular Pathology of Skeletal Development»

Heft Nr. 31:
Preisverleihung 2003
Festbeiträge der beiden Preisträger
Professor Dr. Michael Nip Hall:
«TOR Signalling: from bench to bedside»
PD Dr. Bernhard Moser:
«Chemokines: role in immune cell traffic»

Heft Nr. 32:
Preisverleihung 2004
Festbeiträge der beiden Preisträger
Professor Dr. Amalio Telenti:
«Adaption, co-evolution, and human susceptibility to HIV-1 infection»
Professor Dr. Radek C. Skoda:
«The control of normal and aberrant megakaryopoiesis by thrombopoietin and its receptor, c-MPL.»
Heft Nr. 33:
Preisverleihung 2005
Festbeiträge der beiden Preisträger
Professor Dr. Urs Emanuel Albrecht:
«The circadian clock: orchestrating gene expression and physiology»
Professor Dr. Dominique Muller:
«Functional and structural plasticity of synaptic networks»

Heft Nr. 34:
Preisverleihung 2006
Festbeiträge der beiden Preisträger
Professor Dr. Adrian Merlo:
«Pas de mythe de Sisyphe: Glioma research on the move»
Professor Dr. Michael O. Hengartner:
«Roads to ruin: apoptotic pathways in the nematode Caenorhabditis elegans»

Heft Nr. 35:
Preisverleihung 2007
Festbeiträge der beiden Preisträger
Professor Dr. François Mach:
«Inflammation is a Crucial Feature of Atherosclerosis and a Potential Target to Reduce Cardiovascular Events»
Professor Dr. Nouria Hernandez:
«Mechanisms of RNA Polymerase III Transcriptions in Human Cells»

Heft Nr. 36:
Preisverleihung 2008
Festbeiträge der beiden Preisträger
Professor Dr. Darius Moradpour:
«Hepatitis C: Molecular Virology and Antiviral Targets»
Professor Dr. Sabine Werner:
«Molecular and cellular mechanisms of tissue repair»
Heft Nr. 37:
Preisverleihung 2009
Festbeiträge der beiden Preisträger
Professor Dr. Margot Thome-Miazza:
«Molecular mechanisms controlling lymphocyte proliferation and survival»
Professor Dr. Walter Reith:
«Regulation of antigen presentation in the immune system»

Heft Nr. 38:
Preisverleihung 2010
Festbeiträge der beiden Preisträger
Professor Dr. Christian Lüscher:
«Sucht: Die dunkle Seite des Lernens»
Professor Dr. Burkhard Becher:
«Cytokine networks: the language of the immune system»

Heft Nr. 39:
Preisverleihung 2011
Festbeitrag der Preisträgerin
Professorin Dr. Petra S. Hüppi:
«From Cortex to Classroom»

Heft Nr. 40:
Preisverleihung 2012
Festbeitrag des Preisträgers
Professor Dr. Olaf Blanke:
«Brain Mechanisms of Bodily Self-Consciousness and Subjectivity: Review and Outlook»

Heft Nr. 41:
Preisverleihung 2013
Festbeitrag der Preisträger
Prof. Dr. Andreas Papassotiropoulos und
Prof. Dr. Dominique J.- F. de Quervain
«Genetics of Human Memory; From Gene Hunting to Drug Discovery»
Heft Nr. 42:
Preisverleihung 2014
Festbeiträge der Preisträger
Prof. Dr. Marc Y. Donath
«Targeting Inflammation in the Treatment of Type 2 Diabetes: Time to Start»
Prof. Dr. Henrik Kaessmann
«The Evolution of Mammalian Gene Expression: Dynamics and Phenotypic Impact»

Heft Nr. 43
Preisverleihung 2015
Festbeiträge der Preisträger
Prof. Dr. Dominique Soldati-Favre
«The Ins and Outs of Apicomplexa Invasion and Egress from Infected Cells»
Prof. Dr. Fritjof Helmchen
«Watching Brain Cells in Action: Two-Photon Calcium Imaging of Neural Circuit Dynamics»

Heft Nr. 44
Preisverleihung 2016
Festbeiträge der Preisträger
Prof. Dr. Andreas Lüthi
«The Neuronal Circuitry of Fear and Anxiety»
Prof. Dr. Michel Gilliet
«Role of Innate Immunity in Driving Inflammation: Lessons Learned From the Skin»
EHRENTAFEL
DER PREISTRÄGER

1974 Dr. Urs A. Meyer
1975 PD Dr. Hans Bürgi
1976 Dr. Rui de Sousa
1977 Prof. Dr. Franz Oesch
1978 Dr. Susumu Tonegawa
1979 Prof. Dr. Theodor Koller
   Prof. Dr. Jean-Pierre Kraehnenbuehl
1980 Prof. Dr. Edward W. Flückiger
   PD Dr. Albert Burger
1981 Prof. Dr. Rolf M. Zinkernagel
   Prof. Dr. Peter A. Cerutti
1982 PD Dr. Jürgen Zapf
   PD Dr. Jean-Michel Dayer
1983 Prof. Dr. Peter Böhlen
   PD Dr. Claes B. Wollheim
1984 Prof. Dr. Heidi Diggelmann
   Prof. Dr. Jean-François Borel
1985 Prof. Dr. Hans Thoenen
   Dr. Roberto Montesano
1986 Prof. Dr. Walter Schaffner
   Prof. Dr. Ueli Schibler
1987 Prof. Dr. Jacques Louis
   Prof. Dr. Joachim H. Seelig
1988 Prof. Dr. Jean-Dominique Vassalli
   PD Dr. Hans Hengartner
1989 Prof. Dr. Heini Murer
   Dr. Hugh Robson MacDonald
EHRENTAfel
DER PREISTRÄGER

1990  Prof. Dr. Martin E. Schwab
      Prof. Dr. Denis Monard

1991  PD Dr. Peter J. Meier-Abt
      PD Dr. Jacques Philippe

1992  PD Dr. Leena Kaarina Bruckner-Tuderman
      Prof. Dr. Jürg Tschopp

1993  Dr. Paolo Meda
      Jubiläumsjahr
      Prof. Dr. Adriano Fontana
      Prof. Dr. Michel Aguet

1994  Prof. Dr. Hans Rudolf Brenner
      Prof. Dr. Daniel Pablo Lew

1995  Prof. Dr. Jürg Reichen
      Dr. George Thomas jr.

1996  Dr. Lukas C. Kühn
      Prof. Dr. Peter Sonderegger

1997  Dr. Gérard Waecher
      Prof. Dr. Denis Duboule

1998  Prof. Dr. Adriano Aguzzi
      Prof. Dr. Primus E. Mullis

1999  Prof. Dr. Clemens A. Dahinden
      Prof. Dr. Antonio Lanzavecchia

2000  Prof. Dr. Giuseppe Pantaleo
      Dr. Brian A. Hemmings

2001  Prof. Dr. Isabel Roditi
      Dr. Thierry Calandra

2002  Prof. Dr. Bernard Thorens
      Prof. Dr. Andrea Superti-Furga
EHRENTAFEL
DER PREISTRÄGER

2003  Prof. Dr. Michael Nip Hall
       PD Dr. Bernhard Moser
2004  Prof. Dr. Amalia Telenti
       Prof. Dr. Radek C. Skoda
2005  Prof. Dr. Urs Emanuel Albrecht
       Prof. Dr. Dominique Muller
2006  Prof. Dr. Adrian Merlo
       Prof. Dr. Michael O. Hengartner
2007  Prof. Dr. François Mach
       Prof. Dr. Nouria Hernandez
2008  Prof. Dr. Darius Moradpour
       Prof. Dr. Sabine Werner
2009  Prof. Dr. Margot Thorne-Miazza
       Prof. Dr. Walter Reith
2010  Prof. Dr. Christian Lüscher
       Prof. Dr. Burkhard Becher
2011  Prof. Dr. Petra S. Hüppi
2012  Prof. Dr. Olaf Blanke
2013  Prof. Dr. Andreas Papassotriopoulos
       Prof. Dr. Dominique J.-F. de Quervain
2014  Prof. Dr. Marc Y. Donath
       Prof. Dr. Henrik Kaessmann
2015  Prof. Dr. Dominique Soldati-Favre
       Prof. Dr. Fritjof Helmchen
2016  Prof. Dr. Michel Gilliet
       Prof. Dr. Andreas Lüthi
EHRENTAFEL
DER PREISTRÄGER

2017 Prof. Dr. Denis Jabaudon
      Prof. Dr. Markus G. Manz